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ABBREVIATION  
 
ApoA-I Apolipoprotein A-I 
[1-93]ApoA-I The fibrillogenic N-terminal 93-residue polypeptide of ApoA-I  
GST The gluthatione S-transferase from S. japonicum 
GST-[1-93]ApoA-I  The chimeric protein containing [1-93]ApoA-I fused to GST 
GFP Green Fluorescent Protein 
mnei Recombinant single chain monellin 
oryc Cystatin I from Oryza  sativa L. japonica 
BSA  Bovine serum albumin 
DTT  Dithiotreitole 
RP-HPLC Reverse Phase High Performance Liquid Chromatography 
IEX-C Ion Exchange Chromatography 
LB medium Luria-Bertani medium 
O.D.   Optical density 
PCR Polymerase Chain Reaction 
PVDF Polyvinylidene fluoride 
SDS Sodium-dodecyl-sulfate 
SDS-PAGE Gel-acrylamide electrophoresys in denaturing conditions 
Tris Tris-hydroximetyl-amino methane  
AFM Atomic Force Microscopy 
EM Electron Microscopy 
ANS 8-anilino-1-naphthalenesulphonate 
ThT Thioflavin T 
CDNB 1-chloro-2,4-dinitrobenzene 
CR Congo Red 
RCT Reverse Cholestérol transport 
TFA Trifluoroacetic acid 
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SUMMARY 
 
An increasing number of human diseases is linked to protein misfolding and 
aggregation in amyloid fibrils. Among amyloidogenic proteins, 13 mutated versions of 
apolipoprotein A-I (ApoA-I) have been associated to amyloid diseases. Fibrils are 
mainly constituted by N-terminal fragments of ApoA-I, about 90-100 residue long. We 
recently set up a reliable expression system to produce a recombinant version of 1-
93 polypeptide (named [1-93]ApoA-I) as a pure and stable product. Conformational 
analyses of [1-93]ApoA-I revealed that under acidic conditions the polypeptide rapidly 
converts from random coil to an unstable intermediate with a helical/molten globule 
state, able to bind ANS, as described for the ex vivo isolated polypeptide. This 
species is thought to be a key early intermediate in the fibrillogenic pathway, leading 
to the formation of a β-sheet-based polymeric structure, having amyloid-like features, 
i.e. the ability to bind specific dyes, such as Congo Red (CR) and Thioflavin T (ThT). 
AFM analyses confirmed that [1–93]ApoA-I is able to generate typical amyloid fibrils.  
Furthermore, we were also able to express the 8 amyloidogenic variants of [1–
93]ApoA-I identified so far in patients affected by amyloidosis. The availability of the 
complete panel of pathological ApoA-I polypeptides opens the way to a detailed 
study, presently in progress, aimed at the definition of the impact of each mutation on 
protein aggregation propensity. Preliminary data indicated that almost all mutants 
display an increased aggregation propensity with respect to [1-93]ApoA-I.  
During my stage at the Medical Research Council (MRC) in London, I extended my 
studies to plant cystatins, i.e. protease inhibitors, largely homologous to human 
cystatins, some of which are involved in amylopathies.  Hence, plant cystatins 
represent an interesting model system to shed light on cystatins aggregation. Two 
cystatins were analysed: mnei, a recombinant engineered monellin, and 
oryzacystatin I (oryc), a cystatin from O. sativa. I found that, under acidic conditions, 
both proteins undergo a temperature-driven transition  from β−sheet to random coil, 
that eventually leads to aggregation. Mnei was found to generate typical amyloid 
fibrils, able to bind the amyloid specific dye ThT. No amyloid-like structures were 
instead found to be present in oryc aggregates, whereas stable trimeric species were 
isolated and supposed to prevent protein self-aggregation.  
I also planned to engineer fibrillogenic polypeptides to produce new bio-materials 
obtained by molecular self-assembly. Amyloid fibrils are in fact good candidates to 
construct nanostructured materials, by means of their ordered, polymeric structure. 
Catalytic fibrils were then designed, using a fusion protein, made up of [1-93]ApoA-I 
linked to GST enzyme, as the monomeric unit in a fibrillogenic process. The former 
will act as the fibrillogenic moiety, the latter as the catalytic moiety. The fusion protein 
was expressed and isolated as a pure product, and found to retain both the native 
fold and the catalytic activity of GST enzyme. Moreover, upon incubation under 
slightly acidic conditions, the fusion protein was found to bind ANS, ThT and CR 
dyes, indicating that a pH-driven transition, followed by aggregation in amyloid-like 
structures, occurred. When analysed by AFM, typical protofilaments were detected. 
The high molecular weight fibrillar material, immobilised on filter, was then tested for 
enzymatic activity, by providing in continuous the reaction mixture containing the 
GST substrates. Fibrils were found to be catalytically active. 
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RIASSUNTO 
 
Lo scopo del mio lavoro sperimentale ha riguardato lo studio delle proteine 
fibrillogeniche, una classe di proteine propense ad aggregare in strutture ordinate, le 
fibrille amiloidi, associate a gravi patologie definite amiloidosi. Per dar luogo al 
processo fibrillogenico, tali proteine hanno accesso a conformazioni alternative 
parzialmente destrutturate; per tale motivo le patologie amiloidi sono anche definite 
malattie confomazionali, o da misfolding proteico. 
Negli ultimi anni nuovo interesse è sorto intorno al tema del folding proteico. 
Numerose evidenze, tra cui l’esistenza di proteine natively unfolded, cioè proteine 
parzialmente destrutturate anche in condizioni fisiologiche, hanno suggerito un 
panorama più complesso nell’ambito dello studio del folding proteico. Rispetto alla 
visione classica secondo la quale ad una struttura corrisponde una funzione, una 
interpretazione più ampia del processo di folding proteico prevede per ogni proteina 
l’esistenza di un profilo energetico a più stati, popolati da intermedi transienti solo 
parzialmente strutturati. La proteina esplora tale profilo energetico per raggiungere la 
propria conformazione nativa. La “complessità” del profilo energetico può rendere 
ragione sia del numero diverso di conformazioni che una proteina può assumere, sia 
della velocità con cui essa evolve verso lo stato nativo. Tale modello prevede la 
possibilità che una proteina generi stabilmente oligomeri o aggregati di diverso tipo, 
quando alle interazioni intramolecolari si sostituiscono quelle intermolecolari. Gli 
aggregati proteici si configurano quindi come prodotti del processo di folding 
proteico.  
Eventi destabilizzanti, quali le condizioni del microambiente o la presenza di 
mutazioni, possono essere responsabili della formazione di intermedi proteici 
parzialmente destrutturati. Tali intermedi espongono, o giustappongono, superfici 
nascoste nella struttura nativa, o distanti nello spazio, permettendo l’aggregazione di 
monomeri in strutture polimeriche.  
Le fibrille amiloidi costituiscono aggregati proteici ordinati caratterizzati da una 
struttura polimerica detta β-cross, in cui le molecole della proteina, o sue regioni 
fibrillogeniche, assumono una conformazione a foglietti β disposti 
perpendicolarmente all’asse della fibrilla. L’ osservazione che il medesimo motivo β 
fibrillare sia assunto da proteine non correlate tra loro per struttura o funzione, e che 
numerose proteine possono generare fibrille in vitro, suggerisce che la struttura 
fibrillare sia una forma di organizzazione superstrutturale preservata durante 
l’evoluzione. I depositi proteici generati da proteine distinte, condividendo specifiche 
caratteristiche strutturali, mostrano proprietà comuni, quali la capacità di legare 
specifici coloranti, quali la Tioflavina T (ThT) o il Congo Rosso (CR). 
Un numero sempre crescente di patologie nell’uomo è correlato alla elevata 
propensione di alcune specifiche proteine ad aggregare generando depositi amiloidi 
in organi o tessuti. Tra queste patologie annoveriamo il morbo di Parkinson, il morbo 
di Alzheimer e le encefalopatie spongiformi.  
Più di 20 proteine nell’uomo sono state associate ad amiloidosi: tra queste la 
Apolipoproteina A-I (ApoA-I), il principale costituente della frazione delle lipoproteine 
ad alta densità del siero (HDL). La presenza di specifiche mutazioni nel gene ApoA-I 
genera varianti della proteina riscontrate in pazienti affetti da patologie amiloidi. 
Tredici varianti sono state finora descritte. Nei pazienti affetti da tali amiloidosi, le 
fibrille sono costituite dalla porzione N-terminale di ApoA-I, di lunghezza variabile 
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compresa tra 80 e 100 amminoacidi. Tali polipeptidi sono generati attraverso un 
meccanismo ancora sconosciuto.  
Delle tredici mutazioni associate a patologie, 8 sono localizzate nella regione N-
terminale della proteina corrispondente al  frammento fibrillogenico, e pertanto 
definite mutazioni “interne”; 5 mutazioni invece sono localizzate a valle di tale regione 
(mutazioni “esterne”). Studi effettuati dal gruppo del Prof. V. Bellotti dell’Università di 
Pavia sul polipeptide costituito dai residui 1-93 di ApoA-I, estratto da fibrille isolate 
dal cuore di un paziente sottoposto a trapianto, hanno evidenziato che tale 
polipeptide si può definire natively unfolded in quanto destrutturato in condizioni 
fisiologiche.  
La impossibilità di ottenere sufficiente materiale ex vivo, nonché le difficoltà legate 
alla produzione in forma ricombinante di un polipeptide destrutturato, hanno finora 
limitato la possibilità di analizzare in dettaglio il processo di fibrillogenesi di ApoA-I.  
Nell’ambito del mio progetto di ricerca, ho contribuito a mettere a punto un efficace 
sistema di espressione, che permette di ottenere il polipeptide ricombinante in forma 
pura e stabile, in quantità sufficienti per studi strutturali e funzionali.  
Il cDNA codificante la regione N-terminale di ApoA-I (residui 1-93), clonato in un 
opportuno vettore, è stato espresso come prodotto di fusione con una proteina 
batterica, altamente stabile e solubile, quale l’enzima glutatione S-transferasi (GST 
da S. Japonicum). La proteina di fusione, isolata mediante cromatografia di affinità, è 
stata poi sottoposta a  proteolisi sito-diretta per generare il polipeptide di interesse. 
Quest’ultimo è stato poi isolato all’omogeneità mediante cromatografia a fase 
inversa. Il prodotto ricombinante è stato denominato [1-93]ApoA-I.  
L’analisi conformazionale del polipeptide [1-93]ApoA-I, effettuata mediante dicroismo 
circolare nel lontano ultravioletto, ha dimostrato che in condizioni fisiologiche [1-
93]ApoA-I è una proteina natively unfolded. Abbiamo inoltre dimostrato che, a 
seguito della acidificazione della soluzione (pH 4), il polipeptide  subisce una 
transizione conformazionale da una  struttura random coil ad una struttura ad α-elica, 
come riscontrato anche per il polipeptide estratto ex vivo. Tale transizione è risultata 
reversibile se le condizioni fisiologiche vengono ripristinate.  
Esperimenti di spettrofluorimetria, effettuati utilizzando il fluoroforo 8-anilino-1-
naftalene-solfonato (ANS), hanno indicato che tale composto lega in maniera 
reversibile il polipeptide a pH 4, ciò che indica la presenza di una struttura di tipo 
molten globule. Sulla base di questi dati abbiamo ipotizzato che la struttura α-
elicodale, con caratteristiche di molten globule, è un intermedio chiave nel processo 
di fibrillogenesi e che la sua formazione rappresenta un evento precoce e reversibile 
in questo processo.  
Abbiamo poi dimostrato che la prolungata esposizione del polipeptide in ambiente 
acido induce la conversione dell’intermedio α-elicodale in una struttura 
prevalentemente del tipo β-sheet. La formazione di tale struttura viene seguita da 
aggregazione proteica, come dimostra la scomparsa del segnale di dicroismo 
circolare nel tempo. La caratterizzazione degli aggregati formati dal polipeptide in 
condizioni acide, attraverso l’utilizzo di coloranti specifici per fibrille amiloidi, quali 
Tioflavina T e Congo Rosso, ha evidenziato la presenza della caratteristica struttura 
amilode β-cross. In tali analisi l’abbassamento del valore di pH emerge come un 
evento destabilizzante, in grado di favorire cineticamente la formazione delle fibrille. 
Dai dati riportati è risultato chiaro che le proprietà riscontrate per il polipeptide 
ricombinante sono sovrapponibili a quelle della sua controparte nativa, ciò che 
avvalora l’utilizzo del polipeptide ricombinante come modello per lo studio del 
processo di fibrillogenesi.  
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Ad avvalorare quanto riportato, analisi in silico, effettuate con i comuni algoritmi 
predittivi, hanno mostrato un elevato potenziale fibrillogenico del polipeptide, tanto 
più elevato quanto più acido è il pH. Da tali analisi, la regione compresa tra i residui 
13-25 del polipeptide è risultata presentare il più elevato potenziale fibrillogenico. 
Esperimenti di gel-filtrazione hanno inoltre mostrato che il polipeptide in condizioni 
fisiologiche assume una struttura dimerica. Tali dati sono in accordo con risultati 
precedentemente ottenuti mediante esperimenti di proteolisi limitata, accoppiata a 
spettrometria di massa, condotte dal gruppo del Prof. P. Pucci dell’Università di 
Napoli.  
Infine, dati di microscopia a forza atomica (AFM) hanno dimostrato che il polipeptide 
ricombinante, a seguito dell’incubazione in condizioni di pH acido, è in grado di 
generare tipiche fibrille amiloidi, morfologicamente simili alle fibrille formate dal 
polipeptide naturale, e prodotte in una scala temporale paragonabile.  
L’insieme dei dati ottenuti indica l’esistenza di un complesso processo fibrillogenico a 
più stadi, attraverso cui il polipeptide [1-93]ApoA-I assume diverse conformazioni e 
genera fibrille amiloidi. In tale processo sembra essere determinante il delicato 
equilibrio esistente tra le interazioni stabilizzanti la forma nativa e le interazioni in 
grado di favorire l’aggregazione del polipeptide. 
 
I risultati ottenuti nella caratterizzazione del processo fibrillogenico del polipeptide [1-
93]ApoA-I ci hanno incoraggiato a produrre in forma ricombinante anche le varianti 
del polipeptide riscontrate nei pazienti affetti da amiloidosi.  
Pertanto, ho ottenuto il cDNA codificante ciascuna delle 8 varianti del polipeptide 
fibrillogenico, attraverso esperimenti di mutagenesi sito-diretta del cDNA codificante 
[1-93]ApoA-I. Tra queste varianti, 6 contengono una mutazione puntiforme (G26R, 
T50R, L60R, L64P, L75P e L90P), mentre 2 contengono una delezione della 
sequenza 70-72 e 60-71, rispettivamente (nell’ultimo caso è presente anche 
l’inserzione dei residui VT).  Ciascun cDNA è stato clonato vettore di espressione già 
utilizzato per il polipeptide [1-93]ApoA-I, a valle della sequenza codificante l’enzima 
glutatione-S-transferasi. Seguendo il protocollo precedentemente riportato, ho 
espresso e isolato all’omogeneità le 8 varianti patologiche, ottenendo in questo modo 
il set completo dei mutanti del polipeptide. 
L’ottenimento delle varianti del polipeptide amiloidogenico in forma ricombinante 
risulta essere l’unica strategia utilizzabile per poter affrontare studi strutturali e 
funzionali sulle varianti stesse. Sono attulmente in corso analisi sulla dinamica 
conformazionale e sul potenziale fibrillogenico delle varianti del polipeptide [1-
93]ApoA-I. Dati preliminari hanno dimostrato che le varianti hanno una elevata 
tendenza a generare fibrille, anche più elevata di quella del polipeptide non mutato. 
Tali analisi sono volte a definire l’impatto delle singole mutazioni sul potenziale 
fibrillogenico del polipeptide, e sono un utile strumento per l’identificazione dei 
determinanti molecolari della fibrillogenesi.  
 
Nell’ambito dello studio sulle proteine fibrillogeniche, è parso di interesse effettuare 
studi su alcune cistatine da piante, come proteine modello per lo studio del processo 
di fibrillogenesi delle cistatine umane associate ad amiloidosi. Infatti le cistatine, 
inibitori delle proteasi a cisteina, rappresentano un altro esempio di proteine correlate 
a severe amilopatie. Tra esse annoveriamo la cistatina C, responsabile della 
angiopatia amiloide ereditaria (HCCAA) e la cistatina B implicata nella malattia di 
Unverricht- Lundborg. In entrambi i casi, mutazioni nella sequenza proteica sono 
identificate come il fattore determinante la patologia.  
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Tali studi sono stati effettuati durante il mio soggiorno al Medical Research Council 
(MRC) di Londra, presso il laboratorio della Dott. A. Pastore. 
Le cistatine da pianta (fitocistatine) possono, in particolari condizioni, generare in 
vitro fibrille amiloidi. Inoltre esse condividono con le cistatine umane il tipico motivo 
strutturale delle cistatine, consistente in una singola α-elica intorno alla quale cui si 
dispone un foglietto β a 5 filamenti.  
La monellina, una cistatina dal sapore dolce proveniente dalla bacca tropicale 
Dioscoreophyllum cumminsii, rappresenta il primo caso identificato di proteina 
fibrillogenica da pianta. Delle 2 catene polipeptidiche da cui essa è formata, soltanto 
una, la catena B, è in grado di formare fibrille in condizioni destabilizzanti. 
Ho analizzato la dinamica conformazionale, la stabilità termica e il potenziale 
fibrillogenico di due cistatine da piante. La prima, mnei,  è una monellina 
ricombinante a singola catena polipeptidica, ottenuta collegando con un dipeptide le 
due catene da cui è costituita la monellina wild type; la seconda, oryc,  è la cistatina I 
dalla variante di riso Oryza sativa, la prima cistatina da pianta che è stata ben 
caratterizzata. 
I risultati ottenuti con esperimenti di denaturazione termica hanno mostrato che 
entrambe le proteine sono molto stabili anche a pH acido e subiscono un processo di 
denaturazione termica a due stadi, con assenza di intermedi. Tramite analisi di 
spettroscopia in dicroismo circolare abbiamo dimostrato che entrambe le proteine in 
ambiente acido conservano la tipica struttura delle cistatine. Tuttavia, incrementando 
la temperatura, è stata identificata una transizione dalla struttura β-sheet verso una 
struttura random coil . 
Nel caso della proteina mnei, prolungando l’esposizione in condizioni acide, è stata 
evidenziata una ulteriore transizione verso una struttura β, il cui segnale viene perso 
con il progredire dell’incubazione, ciò che indica la formazione di aggregati insolubili. 
La cinetica di formazione di tali aggregati è stata seguita con il fluoroforo Tioflavina T, 
specifico per le strutture amiliodi. Dopo circa 5 ore di incubazione in ambiente acido, 
è stato possibile identificare aggregati fibrillari con la tipica struttura amiloide β-cross, 
capaci di legare il fluoroforo.  
Durante l’incubazione della cistatina mnei in ambiente acido sono state inoltre 
effettuate analisi per gel-filtrazione, volte a caratterizzare gli aggregati generati. 
Attraverso tali analisi è stato possibile rivelare la progressiva scomparsa nel tempo 
della forma monomerica solubile della proteina, plausibilmente coinvolta nel 
processo di polimerizzazione fibrillogenica. Sono state infine condotte analisi 
preliminari di microscopia a forza atomica su un campione proteico dopo 
incubazione. Da tali analisi è stata evidenziata la presenza di materiale pre-fibrillare 
oltre a quella di aggregati amorfi.  
Analoghi esperimenti sono stati effettuati sulla proteina oryc. Gli aggregati di oryc 
non generano la tipica struttura amiloide fibrillare, come si deduce dall’assenza di 
legame della Tioflavina T. Durante l’incubazione della proteina in ambiente acido 
sono stati condotti esperimenti per gel-filtrazione, con lo scopo di analizzare le specie 
molecolari coinvolte nel processo. In seguito a tali analisi, dopo circa 3 ore di 
incubazione, è stata isolata una forma oligomerica della proteina, dal peso 
molecolare corrispondente ad un trimero. Tale specie si forma a partire da unità 
monomeriche, come si evince dal fatto che la quantità di specie monomeriche 
diminuisce nel tempo, parallelamente all’aumento della specie trimerica.  
Si è ipotizzato che la assenza di polimeri amiloidi durante l’incubazione di oryc sia 
dovuta alla formazione dell’oligomero stabile isolato mediante gel-filtrazione. Questo 
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potrebbe sequestrare il monomero impedendone la polimerizzazione in strutture 
fibrillari.  
 
Infine, il mio progetto di ricerca ha previsto uno studio sulle potenziali applicazioni 
biotecnologiche dei polimeri fibrillari. Infatti, le fibrille amiloidi rappresentano un 
esempio di molecular self-assembly per la costruzione di strutture polimeriche 
ordinate. Il molecular self-assembly opera attraverso il riconoscimento di superfici 
molecolari complementari, che determina una loro stabile associazione. Esso viene 
utilizzato nella costruzione di nuovi materiali attraverso la strategia del bottom-up,  
che opera su singole molecole per costruire strutture supermolecolari. Il molecular 
self-assembly è un meccanismo comunemente utilizzato nel campo delle 
nanobiotecnologie.  
La struttura amiloide rappresenta un elemento di interesse nel campo dei nuovi 
materiali, per le sue specifiche proprietà. E’ un polimero non covalente, periodico e 
ordinato e rappresenta una struttura resistente che può svilupparsi nelle tre 
dimensioni.  
In questo lavoro ho esplorato la possibilità di generare nuove matrici catalitiche 
utilizzando le fibrille amiloidi come supporto a cui legare un enzima di interesse 
biotecnologico. Il termine “fibrille catalitiche” è apparso di recente nell’ambito delle 
nanotecnologie. 
Per costruire fibrille catalitiche, abbiamo utilizzato una proteina di fusione come unità 
base del processo di fibrillogenesi. La proteina di fusione è costituita dall’enzima 
glutatione S-transferasi (GST), che rappresenta la porzione catalitica, e dal 
polipeptide [1-93]ApoA-I, che rappresenta la porzione fibrillogenica. La scelta 
dell’enzima GST è giustificata dal fatto che questo enzima è ampiamente utilizzato in 
ambito biotecnologico, in particolar modo nei processi di detossificazione e di 
bioremediation. La proteina di fusione, definita GST-[1-93]ApoA-I, è stata espressa in 
un opportuno ospite procariotico e successivamente isolata all’omogeneità mediante 
cromatografia di affinità e cromatografia a scambio ionico. 
Per poter realizzare fibrille catalitiche devono essere soddisfatti due requisiti, e cioè 
che l’attività enzimatica della componente catalitica sia preservata durante 
l’aggregazione in fibrille e che la presenza della componente catalitica non ostacoli il 
processo di aggregazione in fibrille. Pertanto il prodotto di fusione, una volta isolato, 
è stato sottoposto ad analisi volte a definire l’attività catalitica e il potenziale 
fibrillogenico. 
La determinazione dell’attività catalitica mediante il saggio del CDNB (1-chloro-2,4-
dinitrobenzene) ha indicato che la proteina di fusione solubile mantiene invariata 
l’attività dell’enzima GST. Inoltre, l’analisi della struttura della proteina di fusione, 
effettuata mediante dicroismo circolare a pH 8.0, ha fornito uno spettro 
sovrapponibile a quello ottenuto con l’enzima GST. Il lieve aumento riscontrato in 
relazione alla struttura random coil della proteina di fusione  è plausibilmente da 
addebitare alla presenza del polipeptide destrutturato [1-93]ApoA-I.  
E’ stato quindi analizzata la capacità della proteina di fusione a generare fibrille 
utilizzando approcci sperimentali indipendenti. In seguito a debole acidificazione del 
valore di pH, si è verificato che la proteina di fusione è in grado di legare il fluoroforo 
ANS, evento da correlare ad una transizione conformazionale, indotta dal pH, verso 
un intermedio parzialmente strutturato a carattere di molten globule. Tale transizione 
è risultata reversibile se il valore di pH era riportato ad 8.0.   
Per verificare che la proteina di fusione fosse in grado di generare tipiche fibrille 
amiloidi, abbiamo condotto saggi spettrofluorimetrici e spettrofotometrici utilizzando 
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coloranti specifici per strutture amiloidi, quali Tioflavina T e Congo Rosso. I risultati 
ottenuti hanno indicato che, dopo circa 40 ore di incubazione in condizioni che 
inducono l’aggregazione, sono presenti tipici aggregati amiloidi generati dalla 
proteina di fusione. In parallelo, il materiale insolubile generato dall’incubazione 
dell’enzima GST è risultato invece negativo alla presenza di strutture fibrillari. Infine, 
le analisi per microscopia a forza atomica, condotte dal gruppo della Prof. A. Gliozzi, 
Università di Genova, hanno dimostrato la presenza di filamenti fibrillari generati 
dalla proteina di fusione. 
Il materiale fibrillare, immobilizzato su filtri di PVDF con cut off pari a 0.02 o 0.2 μm, è 
stato sottoposto ad analisi di attività enzimatica, facendo fluire in continuo attraverso i 
filtri una miscela contenente i substrati della reazione dell’enzima GST. Tale 
procedura ha permesso di dimostrare che il materiale  fibrillare, immobilizzato sulla 
membrana con cut off di 0.02 μm, era cataliticamente attivo, cioè in grado di 
generare il prodotto enzimatico atteso.  
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INTRODUCTION 
 
1. The protein folding problem 
Protein folding is crucial in completing the information transfer from DNA to an active 
protein product [1]. In 1973 C. Anfinsen stated a fundamental principle of the protein 
folding, i.e. the folding of a protein is determined by its amino acid sequence: “ All the 
information necessary to achieve the native conformation of a protein in a given 
environment is contained in its amino acid sequence” [2].  
From this principle derived the structure-function paradigm, claiming that a specific 
function of a protein is determined by its unique and rigid three-dimensional structure. 
However, since from those years, some questions emerged, one of these being the 
Levinthal paradox [3], in consideration of the short time required for protein folding in 
vivo as well as in vitro with respect to the timescale for a  random-search mechanism 
for protein folding.  
More recently, “natively unfolded” proteins emerged [4] as proteins  lacking of almost 
any secondary structure and shown to be extremely flexible and disordered under 
physiological conditions [5]. This proteins are also called "natively denatured" [6], 
"intrinsically unstructured" [7] or "intrinsically disordered" [8]. In 2000, more than 100 
proteins were classified as natively unfolded [9], this number being actually greater. 
The main feature of these proteins is the intrinsic structural plasticity, meaning that 
they can undergo a disorder to order transition upon functioning [10,11,7]. 
Finally, in spite of the great number of proteins in all known organisms (1011), through 
the exploration of the Protein Data Bank (PDB) less than 700 different folds have 
been observed to date and the proteins domains exhibit only 32 types of different 
architectures [13].  
These evidence led to a reconsideration of the protein folding problem. Even if more 
folding models were proposed in the last 30 years, actually the most reliable one is 
the energy landscape, funnel-like model, proposed by P.G. Wolynes: “to fold, a 
protein navigates with remarkable ease through a complicated landscape” [14].  
The so called “new view” of the protein folding shows that an ensemble of unfolded 
polypeptide chains search for a predominantly native state on a usually rugged 
energy surface, or 'landscape', through a transient ensemble of  partially folded 
species (Fig .1). This model presents some advantages: 
1. It can be adapted to different proteins. For small proteins this landscape 
appears to be smoother and the folding is very fast and follows a two state 
pathway, with only two species being stably populated , i.e. the ensemble of 
unfolded structure and the native state.  In contrast, larger proteins have a 
rougher energy landscape, which indicates a slower and multistate folding that 
allows the population of partially folded species. These species may be on-
pathway if they are productive for the correct folding or off-pathway if they are 
traps that inhibit the protein folding. 
2. It takes in account both the kinetic and thermodynamic aspects of the folding 
pathway. The folding rate is slowed by ripples in the energy landscape 
corresponding to local minima populated by transiently stable intermediates. 
Kinetic  traps  arise from energy barriers; when barriers are high enough the 
protein is trapped. By contrast, the steeper the slope, the faster the folding.  
Towards the bottom of the folding funnel, the number of protein conformations 
decreases, as does the chain entropy. According to the model, there are 
parallel micropathways that form microstructures in several region of the 
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protein reducing the number of possible conformation. The Levinthal paradox 
is so removed. 
3. It provides the way to understand the formation of stable species different from 
the native structure, like aggregates, oligomers or fibrils. A competition 
between intramolecular, native-like interactions and intermolecular, non native 
interactions occurs generating fluctuations in the unfolded or partially folded 
ensemble. The former drive the reaction towards the native structure, the latter 
drive the reaction towards other stable structures. 
 
 
 
Fig. 1: Energy landscape for protein folding and aggregation. The surface 
illustrates the roughness of the protein energy landscape, showing the multitude 
of conformational states available to a polypeptide chain. Rather simple folding 
funnels (light grey) can describe the conformational search of a single 
polypeptide chain to a functional monomer by means of intramolecular 
interaction. Intermolecular protein association dramatically increases 
ruggedness (dark grey). Arrows indicate the proposed pathways linking the 
conformational states represented in figure. 
By means of NMR methods and X-ray crystallography, much is known about the 
structure of proteins in their native conformations. Aggregates and amyloid fibrils are 
actually under studies as crucial in the emerging diseases called amyloidosis (see 
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later). On the other hand, the conformational properties of unfolded proteins and 
partially folded states are more difficult to define because of their heterogeneity, 
e folding, as they occur  within the dead 
tured, hydrophobic interactions are 
eins, the rate-limiting step requires the 
folding, 
l
es add important information to the 
 
e, or the 
biquitin-independent autophagy, remove proteins with an incorrect folding. 
complexity and rapid interconversion.  
Early intermediates belonging to the ensemble of partially folded states are the 
hydrophobic collapsed state,  the pre-molten globule and the molten globule state, 
occurring in this order in the pathway towards the folded state. The time scale of the 
appearance of these intermediates range between nanosec to millisec, making 
difficult the analyses of the initial events of th
time of the most common analytical device. 
Better characterized is the molten globule state,  a general intermediate in the folding 
pathway of proteins. It is a compact intermediate with a high content of native 
secondary structure [15, 16], but a fluctuating tertiary structure. It contains accessible 
hydrophobic surfaces which bind a hydrophobic dye, anilinonaphtalene  sulphonate 
(ANS); this behavior should be considered as a characteristic property of the molten 
globule state [17,18]. Finally the molten globule state appears as a heterogeneous 
species, in which the helical domain is struc
fluctuating and the β sheet is rather disordered. 
In the final rate-limiting step, the protein achieves its native conformation with the 
emergence of functional properties. These final events correspond to the precise 
ordering of the elements of secondary structure, the correct packing of the 
hydrophobic core, the correct domain pairing in multidomain proteins, the reshuffling 
of disulfide bonds by the protein disulfide isomerase, the cis-trans proline 
isomerization by peptidyl-prolyl-cis-trans isomerase and the subunit assembly in 
oligomeric proteins. For several prot
reorganization of misfolded species [19] 
A multidisciplinary approach is commonly used to investigate the protein 
encompassing biophysic, biochemistry, biology, medicine and mathematics.  
X-ray crystallography, by means of  missed electron density [20] and NMR 
techniques, including solid state NMR,  has been successfully used  to analyze 
several unfolded, partially folded and aggregated proteins [7]. Near UV CD and Far-
UV CD spectra are characteristic of protein tertiary and secondary structures [21] and 
can be used to determine conformational changes or aggregation [22, 23].  Protein 
denaturation may be easily detected with CD analyses too. Techniques such as gel-
filtration, sedimentation, and dynamic and static light scattering may help in defining 
the compactness of a protein [9]. Additional knowledge on the compactness of a 
protein structures may be extracted from the analysis of different fluorescence or 
colorimetric characteristics. Increased proteolytic degradation in vitro can indirectly 
confirm an increased protein flexibility or accessibility [8].  Immunochemical methods 
may also be applied toward the elucidation of protein structura  changes [24]  and 
aggregation [25]. Overall, these techniqu
conformational description of a polypeptide. 
These are the most common techniques used in protein folding characterization,
even if advances in these methodology have been recently made, not reported here. 
Finally, it has to be considered that protein folding occurs in vivo where the 
complexity of the pathway drastically increases, as phenomena like protein crowding 
or confining act on the protein folding in a manner not always predictable. Moreover, 
molecular chaperones have a role in preventing improper folding and subsequent 
aggregation, while degrading systems, like the ubiqitin-dependent proteasom
u
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2. Protein aggregation and diseases. 
Protein aggregation is  a side reaction along the folding pathway that can generate 
oligomers, disordered aggregates, i.e. amorphous aggregate, or highly ordered 
aggregates, i.e. amyloid fibrils, as shown in Fig. 1. 
The generally accepted hypothesis for protein aggregation is that either from partial 
structuring of unfolded polypeptide (refolding model), or from limited conformational 
changes in native structure (gain of interaction model), a set of partially folded 
intermediates is populated [26] (Fig. 2). In these intermediates aggregation 
competent regions previously buried are exposed, thus permitting aggregation. In the 
initial stages of aggregation, surface elements of one molecule interact with matching 
surface areas of neighbouring molecules [27] Even if the major driving forces, i.e. the 
formation of hydrogen bonds and the burial of hydrophobic surface area, are 
commonly involved in both protein folding and aggregation, specific residues are 
involved [28] and intermolecular interactions promote aggregation, while 
tramolecular  interactions promote protein folding [49].  in
 
 
 
Amyloid fibrils are formed with nucleation-dependent polymerisation, in which the 
protein monomer is converted into a fibrillar structure via a transiently populated 
aggregation nucleus [29]. Following the rate-limiting step of nucleus formation, which 
results in the presence of a typical lag-phase, aggregate growth proceeds rapidly by 
Fig. 2. Proposed mechanisms of protein aggregation. Amyloid fibril formation 
proceeds from intermediate partially folded states that are formed via partial 
unfolding of the native structure, or via the partial structuring of unfolded 
polypeptides. Ordered aggregates associate via mechanisms such as domain 
swapping (ds), strand association (sa) or β-strand stacking (bs). Self-association 
of these early oligomeric species, possibly involving further conformational 
changes, leads to the formation of amyloid fibrils. 
further addition of monomers, or other assembly-competent oligomers, to form larger 
polymers. Growing polymers are commonly called protofibrils. 
The formation of protein oligomers requires a critical concentration of proteins [29, 
30] Basing on kinetic modelling of protein aggregation, the early protein oligomers act 
as seeds facilitating protein misfolding and promoting protein polymerization and 
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eventually fibrils formation [31]. In the slow lag phase, a series of kinetically 
unfavourable interactions occurs to form the oligomeric nucleus that rapidly grows to 
form larger polymers. In the nucleation dependent polymerization model the lag 
phase can be shortened in the presence of small amount of preformed fibril seeds. 
According to the recycling hypothesis, an equilibrium is reached on the growing 
ine. However, in all proposed mechanisms a specific protein 
utation and intrinsic instability [57, 58], 
ses (see later) suggests a crucial role of cellular 
on-crystalline, the typical amyloid structure is 
[48]. However, other 
t introduced by Schleiden in 1838 to describe plant starch, in 
surface of the fibrils between associating and dissociating molecules as in a 
reversible reaction [32].   
As shown in Fig. 2, three main mechanisms are proposed for amyloid fibril formation. 
In the strand association mechanism, the amyloid fold occurs via the direct stacking 
of single protein subunits [33]. By contrast, in the domain swapping model an 
exchange of a specific domain between the assembling subunits is required, but the 
main protein fold remains the same [35, 36]. In the generic β−cross spine mechanism 
[34], the fibrils grow by providing short polypeptide segments that stack together to 
form the stable fibril sp
destabilisation is required, that results in an increased population of the partially 
folded conformations. 
In vitro destabilization depends from protein m
protein concentration, pH [38], temperature [37], ionic strength, metals or redox 
environments [39], co-solute or denaturants.  
In vivo destabilization depends also from the presence of abnormal proteolytic 
cleavage [40],  the impairing of the cell proteasome [41] and the role of chaperones 
[42], the protein crowding and confining [43], the changes in local environment, the 
altered post translational modification or genetic defects [40, 57]. The late onset of 
aggregation related disea
mechanisms for removing the aggregates, which becomes ineffective or 
overwhelmed with the age. 
In spite of the difficulties to obtain high-resolution structures of amyloid fibrils, as 
these species are insoluble and n
defined in terms of empirical observations from X-ray fibre diffraction, EM/AFM and 
specific chemical staining [44, 45].  
The first definition of amyloid as possessing a generic cross-β structure was made 
nearly 40 years ago [46]. EM and AFM studies have shown that amyloid fibrils are 
straight, unbranched and about 70–120 Å in diameter [47]. They are composed of 
several protofilaments, each protofilament consisting of contiguous β-pleated-sheet 
polypeptide chains, perpendicularly aligned to the long axes of the fibers (cross 
β−pleated sheets). Fibrils of different diameters and morphologies have been 
observed, related to the so called amyloid fibrils polymorphism [56, 70]. Furthermore, 
green birefringence upon staining with Congo red, or the fluorescence shift after 
staining with ThT, are also classical features of the amyloid fold 
techniques are now commonly used to detect amyloid aggregates, like 
ultracentrifuge, light scattering or gel-filtration chromatography.  
An increasing number of human diseases has been linked to protein aggregation and 
to the aberrant accumulation of protein deposits in different tissues and organs [49, 
50]. These disorders are collectively known as protein misfolding or conformational 
diseases [51, 52], because the pathological protein undergoes structural changes 
that results in self-association, aggregation and tissue deposition. The pathological 
proteins are called chameleon protein indicating their conformational plasticity [53]. 
When protein aggregates result in ordered, insoluble, mainly extracellular deposits, 
the related diseases are called amyloidoses. Rudolph Virchow in 1854 adopted the 
term "amyloid", firs
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referring to tissue deposits of material that stained in a similarly to cellulose when 
exposed to iodine. 
In amyloid diseases the protein deposits contain fibrillar protein assemblies 
characterized by the specific dye-binding and tinctorial properties, the cross-β X-ray 
fibre diffraction pattern and macroscopic long, straight and unbranched morphology 
previously described. Deposits can be almost undetectable, or reach kilograms of 
deposited protein [54] and  always contain carbohydrates and other proteins. 
alopathies (or prion encephalopathies), ataxias, etc. All these 
ble length [59]. They are all characterized by a β-cross 
peat structure [60]. Table I summarizes the amyloidogenic proteins and the 
corresponding pathologies. 
 
Precursor protein 
Depending on the localization of the deposits, amyloidoses can be systemic or 
localized [55]. 
Conformational diseases include Alzheimer’s, Parkinson’s and  Huntington diseases, 
spongiform enceph
diseases have a high impact on public health, considering the late onset and the 
degenerative trait.  
There are more than 20 human amyloidogenic proteins known to abnormally self-
assemble into fibrils of varia
re
Clinical syndrome Fibril component 
Alzheimer’s disease precursor Aβ 3 
Amyloid protein -Peptide 1-40 to 1-4
Primary systemic 
amyloidosis 
Immunoglobulin light 
chain 
Intact light chain or 
fragments 
Secondary systemic 
amyloidosis Serum amyloid A 
Amyloid A (76-residue 
fragment) 
Senile systemic amyloidosis Transthyretin fragments 
Transthyretin or 
Hereditary cerebral amyloid Cystatin C minus 10 
angiopathy Cystatin C residues 
He d modialysis-relate
amyloidosis β2-Microglobulin β2-Microglobulin 
Familial amyloid 
polyneuropathy III 
N-terminal fragments of Apolipoprotein A-I apolipoprotein A-I 
Type II diabetes Islet amyloid polypeptide (IAPP) Fragment of IAPP 
Spongiform 
encephalopathies Prion 
Prion or fragments 
thereof 
Hereditary non-neuropathic 
systemic amyloidosis Lysozyme 
Lysozyme or fragments 
thereof 
I  njection-localized
amyloidosis Insulin Insulin 
Hereditary renal 
amyloidosis Fibrinogen Fibrinogen fragments 
 
Table I: The most common amyloidoses, the corresponding pathogenic protein 
precursor and their components detected in the amyloid fibrils.                   
 
Fig. 3 shows some proteins able to form amyloid fibrils, ranging from natively 
unfolded polypeptides, through polypeptides possessing extensive α-helical 
  16
structure, to proteins containing β-sheet structure. Aggregation prone stretches are 
also indicated, identified using the most common algorithm for predicting propensity 
of proteins to aggregate, the TANGO algorithm [62]. The extreme diversity in 
structure and function of proteins associated with amyloid fibrils in human diseases, 
together with the observation that many proteins (i.e. RNase A or mioglobin) not 
related to amyloidoses are able to form in vitro fibrils, suggests that the amyloid fold 
is an ancestral motive preserved during the evolution, a universal, inherent property  
f all polypeptide chains related to the global free-energy minimum (the 
rnating polar and non polar amino acids [77] are thought to be 
o
thermodynamic ground state of the aggregation).  
 
 
 
Two main reasons may explain the persistence of the  amyloid folding motif. It has 
been hypothesized that has a functional active role [61], or, alternatively, that it 
protects cells toward cytotoxic misfolded proteins or early aggregates [63]. In fact, in 
bacteria [66, 67], fungi [64, 69] insects [68] and also in humans [65] different 
processes have been related to the amyloid structure, like structure maintenance, 
information transfer, human hemostasis and mammals melanin biosynthesis. With 
respect to the supposed protective role of amyloid 
Fig. 3. Representative structures of proteins involved in disease-related 
amyloid fibril formation. The coloured regions are polypeptides with high
aggregation propensity, predicted according to the Tango algorithm.
Sequences shown in blue are predicted to have no β-aggregation propensity, 
while polypeptide stretches coloured in yellow, orange and red indicate an 
increasing propensity to aggregate. Notably, the proteins shown are different in
structure and function. 
structures, amyloid fibrils are 
thought to be not  cytotoxic, in contrast with early aggregates occurring during protein 
misfolding and having inherent toxicity [63, 104, 106].  
Even if there is no a clear relationship between protein sequences and aggregation, 
proteins able to aggregate are characterized by a low sequence complexity [71] 
and/or high net charge coupled with low mean hydrophobicity [72] and by the 
abundance of residues favouring the β-sheet secondary structure [74]. By contrast, 
proline or glycine residues [73, 75], edge strands in native β-sheets structure [76], or 
a long stretch of alte
negative determinants in amyloid fibril formation and are  commonly called “structural 
gatekeepers” [78].   
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One of the most interesting features of conformational diseases is the mechanism of 
infectivity. S. Prusiner in 1982, while studying the prion disease, established the 
“protein only” concept, i.e. the existence of a “proteinaceous infectious particle that 
lacks nucleic acid” [79]. Indeed, no nucleic acid has been found to be involved in the 
propagation of the infectious agent. Prion diseases may result from genetic, 
infectious or sporadic disorders, but in each case an aberrant conformational change 
in a protein is propagated. The self-replication of conformational information enables 
prions to create a conformational memory [81] and to transmit the disease [80] even 
if only in a species-specific manner. Prion particles with the same polypeptide 
equence can have distinct physiological effects associated to different 
erse cholesterol transport (RCT). Because of its active 
tion 
f unesterified cholesterol into cholesteryl ester by the enzyme 
r phospholipid transfer protein (PLTP) This suggests a 
g a unique defined tertiary structure [90]. 
olar face that interacts with water. By contrast, the N-
s
conformational states of prion structure [82, 83]. 
 
3. Apolipoprotein A-I and amyloidosis.  
Human apolipoprotein A-I (ApoA-I) represents the major structural component of the 
serum high density lipoproteins (HDL), having the ability to avidly bind lipids [84]. 
ApoA-I plays a critical role in lipid metabolism [85], both in delivering cholesterol to 
steroidogenic tissues and in transporting it from the periphery to the liver for 
catabolism, in the so called rev
role in RCT, it exerts an anti-atherogenic activity in vivo protecting against 
cardiovascular diseases [86]. 
The liver and the intestine synthesize ApoA-I; about 5-10% of human plasma ApoA-I 
exists in a lipid free state. By contrast, ApoA-I represents roughly 70% of the HDL 
protein mass. ApoA-I gene is located on the long arm of chromosome 11. The protein 
is synthesized as a pre-pro-protein of 243 amino acids. After the cleavage of the 18-
residue signal polypeptide, the pro-protein is secreted in the plasma, where the 6-
residue pro-peptide is removed by cleavage by a still unidentified metalloprotease 
[87]. The mature, circulating ApoA-I protein consists of a single polypeptide with a 28 
kDa mass. Transcriptional regulation of ApoA-I gene is complex, involving induc
by several hormones [88] and inhibition by anti-oxidant molecules [89]. No post 
translational modifications, like glycosilation or disulfide bonds formation, occur.   
Upon binding to lipids, the secreted lipid free ApoA-I generates the nascent, discoidal 
HDL. The conversion o
lecithin:cholesterol acyltransferase (LCAT) converts the nascent, discoidal HDL into 
mature spherical HDL. 
During the lipid transport, ApoA-I adopts different lipid association states and 
interacts with several receptors, like the ATP binding cassette transporter (ABCA1) or 
the scravenger receptor (SR-B1), as well as with enzymes, like LCAT, cholesteryl 
ester transfer protein (CETP) o
great conformational plasticity of the protein, commonly included in the natively 
unfolded protein group [105].  
The protein likely exists as an ensemble of related and interconverting species, 
including a molten globule state lackin
ApoA-I catabolism is complex as it requires HDL dissociation. The kidney is the 
principal site of ApoA-I degradation [91]. 
A comparative analysis of the primary structure of ApoA-I of mammals shows that the 
N-terminal region is highly conserved [92]. Secondary structure analyses show that 
the protein is organized into eight α-helical segments of 22 amino acids and two 11-
mer repeats that are frequently separated by proline residues [93]. (Fig 4A). These 
helices are predicted to be amphipathic with a hydrophobic face that likely mediates 
lipid interactions and a p
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terminal region contains the most ambiguously defined structure of the protein, being 
this region highly flexible. 
To date, two crystal structure of ApoA-I are deposited, showing very different 
structures. The full-length lipid free ApoA-I was crystallized by Ajees et al. [94] (PDB 
2A01) The structure (Fig. 4B) indicates that the N-terminal two-thirds of the molecule 
s and the tetramerisation, the latter structure appeared to be more 
pplicable to lipid-bound ApoA-I, while the former structure is more consistent with a 
riants have been reported, half of them 
e complete list of 
ted for each mutant. 
ave also 
tion of 
in a 
position located externally to the fibrillogenic polypeptide (external mutations). 
Analysis of the amyloid fibrils extracted from patients affected by ApoA-I derived 
is involved in an intramolecular four-helix bundle organization, while the 50 residue 
C-terminal region forms an independent hairpin domain.  
Borhani et al. [95] (PDB 1AV1) crystallized a deletion mutant lacking the N-terminal 
43 amino acids. The structure (Fig. 4C) shows a ring-shaped assembly of four ApoA-
I molecules arranged in extended, kinked α-helices. However, because of the 
missing N-terminu
a
lipid-free ApoA-I. 
 
 
 
More than 50 naturally occurring ApoA-I va
Fig. 4: (A), ApoA-I secondary structure prediction; (B), lipid free ApoA-I crystal 
structure (in red the N-terminal region); (C), the crystal structure of ApoA-I 
B A C 
proposed for the lipid-bound state. 
associated with HDL reduced levels [96]. Among them, ApoA-IMILANO variant exerts a 
protective role against atherosclerosis [97].  
Several variants of ApoA-I are associated to amyloid diseases [84]. These variants 
aggregate in vivo and form amyloid fibril protein deposits with the typical β-cross 
structure [70, 84]. Fibrils accumulate in tissues and organs, causing severe 
consequences such as heart, renal or liver failure [98] (Fig. 5A). Th
the 13 ApoA-I amyloidogenic mutations is reported in Fig. 5B and Table II. In the 
latter, the affected organs or tissues are indica
The main trait of all ApoA-I amyloidoses is an autosomic dominant transmission. All  
patients have single heterozygous mutations. 
Most of  the mutants are generated by single point mutations in the 243-amino acid 
sequence of the native protein, although deletions or deletions/insertions h
been described [57, 99, 100]. Some of the single point mutations add a polar or a 
positively charged amino acid, while other mutations add a proline residue.  
In ApoA-I variants, the mutation is either positioned inside the N-terminal por
the protein that is eventually found in fibrils (internal mutations), or it occurs 
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Mutant Organ or Tissue Ethnic origin 
Gly26Arg Nervous system, Kidney USA, UK, Scandinavy, Ireland 
Trp50Arg Liver, Kidney UK 
Leu60Arg Kidney UK 
Δ60/71 
insVal/Thr Liver Spain 
Leu64Pro Kidney n.s. 
Δ70-72 Kidney South Africa 
Leu75Pro Liver, Kidney Italy, USA 
Leu90Pro Heart, Skin France 
ΔLys107  n.s. 
Arg173Pro Heart, Larynges, Skin USA, Caucaso 
Leu174Ser Heart Italy 
Ala175Pro  n.s. 
Leu178His Heart, Larynges, Skin France 
B 
A 
Fig. 5: (A), Increased dimension heart section from a transplanted patient
affected by ApoA-I amyloidosis. (B), A map of ApoA-I amyloidogenic “internal” 
and “external” mutations. Single point mutations (vertical white bars), insertions
(horizontal white bars) or deletions (horizontal blue bars) are indicated.  
Table II: The mutations occurring in ApoA-I sequence, associated to amyloid 
pathology. The affected organs or tissues and the ethnic origins are also indicated. 
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amyloidosis has shown that natural fibrils consist of ApoA-I N-terminal fragments 80-
100 residues long.  
For both external and internal mutations the about 10 kDa N-terminal ApoA-I 
polypeptide represents the main protein species in amyloid fibrils.  
In particular, the ApoA-I variant carrying the substitution of leucine at position 174 
with serine (L174S) [101] is associated with a severe hereditary systemic amyloidosis 
predominantly involving the heart. Amyloid fibrils, extracted from a heart transplanted 
patient were found to be mainly constituted by the amino terminal polypeptide 
(residues 1-93) of ApoA-I [101, 149]. The point mutation located at position 174 of full 
length ApoA-I renders this protein prone to be cleaved by an unknown protease, 
releasing the amino terminal polypeptide. 
Polypeptide 1-93 extracted from ex vivo amyloid deposits was found to be largely 
unstructured at neutral pH, but intrinsically amyloidogenic and able to form 
aggregates and fibrils upon acidification [102]. A complex fibrillogenic pathway, in 
which the fibrillogenic polypeptide assumes a random coil structure at neutral pH, 
shifts into an unstable helical conformation at acidic pH and then aggregates in to a 
β-sheet-based polymeric structure, was envisaged  [102]. Interaction of the 
amyloidogenic polypeptide with phospholipids prevents the switch from the unstable 
helical conformation to the β−sheet form. Moreover, by atomic force microscopy an 
ultrastructural description was performed on the natural amyloid material extracted 
from the heart of a transplanted patient, showing the presence of both globular 
aggregates and fibrils [103]. The fibrils appeared classically twisted and composed 
by three protofilaments. 
Nevertheless, the possibility to elucidate the complex and intriguing fibrillogenic 
pathway of ApoA-I amyloidogenic polypeptide had been limited so far, due to the low 
amount available from in vivo sources. 
Recently, in the laboratories of Prof. Piccoli of the University of Naples, an effective 
and reliable expression system has been settled to produce a recombinant version of 
1-93 polypeptide as a pure and stable product, suitable for conformational and 
fibrillogenic studies.  
 
4. Cystatins and amyloidosis 
Cystatins are a family of small proteins whose main characteristic is that of being a  
cysteine protease inhibitors [107]. Cysteine protease inhibitors are widely distributed 
in mammals, plants, and insects and may function to protect cells from unwanted 
proteolysis and to control intra- and extracellular protein breakdown. They are acidic 
proteins typically composed of 100-120 amino acids, with 4 conserved cysteine 
residues that form 2 disulphide bonds [108].  
During the 1980s, several sequences with high omology to cystatins were 
discovered. Although some of them are not endowed with inhibitory properties and 
do not contain disulphide bridges, they were collectively classified, together with 
cystatins, in the cystatin “superfamily” [109]. The cystatin superfamily consists of 
tightly and reversibly binding inhibitors of cysteine proteases of the papain family. It in 
higher animals can be divided into three types, based on the molecular mass and the 
presence of disulfide bonds (1-3). Type I animal cystatins, about 100 amino acid 
long, lack disulfide bonds, and are present predominantly in the intracellular 
compartment. Type II cystatins, about 120 amino acid long, contain at least two 
characteristic disulfide bonds and are found extracellularly, in body fluids. Type III 
cystatins are larger glycoproteins containing several type 2-like cystatin domains. 
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Thus far, the crystal structure of several cystatins, including human cystatin B (also 
referred to as stefin B) (PDB 1stf) [110] and human cystatin A  (also referred to as 
stefin A) (PDB 1dvc) [111, 112] have been resolved. These structures have shown 
that cystatins share a common typical fold, consisting of a five-stranded antiparallel 
β−sheet structure that wraps around a central α-helix (Fig. 6A).  
 
 
 
Fig. 6: (A) Cystatin A (PDB 1dvc) structure showing the common typical fold 
consisting of a five-stranded antiparallel β-sheet structure that wraps around a 
central α−helix. (B) 3D domain swapped cystatin C  (PDB 1tij). The two chains 
are in green and blue respectively. 
B A 
Some cystatins are involved in human amylopathies. Amyloid aggregates of human 
cystatin C are found, together with the amyloid Aβ polypeptide, in brain arteries of old 
people affected by cerebral amyloid angiopathy [113, 114]. In addition, human 
cystatin C plays an important role in the development of cerebral hemorrhage in 
people with hereditary cystatin c amyloid angiopaty (HCCAA), an autosomal 
dominant desease characterized by the accumulation of amyloid fibrils in many 
tissues, including cerebral arteries [115]. Patients affected by HCCAA harbor a 
mutated version of cystatin C, with leucine 68 mutated to a glutamine, that gives rise 
to deposits of amyloid fibrils in the cerebral arteries, resulting in brain hemorrhage 
and death in young adults [116]. Recently, loss of function mutation in the gene 
encoding human cystatin B, has been suggested as a possible cause of a severe 
neurological disorder known as the Unverricht-Lundborg disease [117].  
For human cystatin C,  a detailed mechanism of amyloid fibril formation has been 
proposed. The solid state structure of wild type cystatin C [118] (PDB 1g96) is a very 
stable dimer originating from 3D domain swapping [119] (Fig. 6B). This observation 
led Janowsky et al. to suggest also a three dimensional domain swapping process to 
explain the formation of cystatin C amyloid fibrils [118, 120]. Domain swapping has 
recently been associated to cystatin C amyloid angiopaty [115] and to Unverricht-
Lundborg disease [120]. Staniforth R.A et al. [121] discussed the  way in which the 
domain swapped dimer of cystatins could propagate into fibrillar structure. Human 
cystatin A and B are found to form amyloid fibrils in vitro too, even if with different 
propensity [122]. 
It has been found that  some plant cystatins, under certain conditions are able to in 
vitro self-aggregate generating  typical amyloid fibrils. The fold of plant cystatin 
resembles that of a pathologically relevant human cystatin, the human cystatin C. For 
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these reasons, plant cystatins are thought to be a useful model to study the protein 
self-aggregation phenomenon and the amyloid fibril formation.  
The first report on the aggregation of a plant cystatin in amyloid fibrils concerns 
monellin [123]. It was found that the isolated B chain, when treated under harsh 
conditions [124], is able to form in vitro amyloid fibrils with the typical tinctorial and 
morphological properties. The observation of amyloid fibrils formation from a plant 
protein strongly support the view that amyloid-like aggregation is a universal 
phenomenon occurring in a very wide range of protein species  [125, 126]. 
Cystatins from plants, homologous to animal cystatins, are referred to as 
phytocystatins [127]. Oryzacystatin (oryc) is the first well defined phytocystatin [128, 
129]. It occurs in the endosperm of the rice Oryza sativa L. japonica, where it shows 
a potent inhibitory activity towards papain (EC 3.4.22.2) and other cysteine 
proteinases. Oryzacystatin is similar to type I animal cystatins,  in that it consists of 
102 amino acids and lacks disulfide bonds, even if its tertiary structure is more similar 
to those of the type 2 animal cystatins. 
Another well characterized plant cystatin is monellin, isolated from the fruit of the 
tropical West African berry Dioscoreophyllum cumminsii [130, 131]. It is a sweet-
tasting protein composed of two subunits, one being 45 residues (A chain) and the 
other 50 residues (B chain) [132]. X-ray and NMR analyses have resolved the 
structure of monellin showing the typical cystatin superfamily fold with five anti-
parallel β-sheets and one α-helix [133, 134, 135]. However, monellin structure lacks 
of the N-terminal region of the cystatins that is known to host one of the essential 
molecular determinants for cysteine protease inhibition. As a consequence, monellin 
lacks of inhibitory activity. The protein is very stable upon acidification, although it is 
rather easily denatured by temperature or chemical reagents.  
In the last years, native monellin has been engineered by fusing the two chains of the 
protein one to each other. Two mutants were prepared: a  single chain monellin 
(named SCM) obtained by joining the C-terminal residue of the B chain directly to the 
N-terminal residue of the A chain [136], and a single chain monellin (named mnei) 
obtained by linking B and A chains via the Gly-Phe dipeptide [137]. These proteins 
retain both the structure and the sweet taste of native monellin, but their thermal 
stability greatly increased. Only one of these variants, the SCM, has been analyzed, 
so far, for its propensity to generate fibrils. It was found that this variant is not able to 
form amyloid fibrils, in contrast to the native protein. 
 
5. Amyloid and Biotechnology  
The amyloid fold, consisting of a continuous β-sheet with β-strands oriented 
perpendicular to the fibril long axis, has been successfully used for biotechnological 
applications. Actually, it presents four main advantages.  
First, the amyloid structure has a remarkable regularity, being periodical and well 
ordered.  
Second, it permits to explore the nanoscale, manipulating individual atoms and 
molecules, as proposed by R. Feynman in 1959 (“I want to talk about the problem of 
manipulating and controlling things on a small scale”)[138].  
Third, using the natural “own” materials, like proteins and peptides, it presents the 
biocompatibility trait.  
Last, it is based on the molecular self-assembly (“molecular Lego”) generating 
structures with a lower complexity than the supramolecular structures [145].  
Molecular self-assembly takes place upon molecular recognition, followed by 
reversible association. It is mediated by weak, non covalent bonds and by 
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complementarity in shapes among the individual building blocks.  Molecular self-
assembly realizes the bottom-up strategy [139] using single molecules as building 
blocks for supramolecular structure. This strategy replaces the top-down approach, 
i.e. the scale down grinding of large materials to obtain smaller entities. Molecular 
self-assembly is emerging as a new route to produce novel materials and to 
complement other materials [146, 147].  
Moreover, the dependence of the amyloid formation from the environmental 
conditions like pH, ionic strength, presence of co-solvents etc, permits to strictly 
chose and control the best options. 
Amyloidogenic polypeptides, like the amyloid β peptide (Aβ) and yeast prion Sup 35, 
were successfully used to cast metal nanowires and to build conducting nanowires, 
respectively [140, 141]. Amyloid fibrils of bioadhesive proteins  were discovered in 
natural adhesives and used to create self assembling biomaterials with novel elastic 
and adhesive properties [142, 143]. Multifunctional peptide fibrils were used as 
biomedical materials for  tissue regeneration and engineering [144]. Novel biomimetic 
nanocomposites [151] and copolymers [152] were obtained using the high propensity 
to generate β-sheet based structures of polypeptides from natural spider silk [148, 
150]. Several self-assembling peptides and proteins that form nanotubes, helical 
ribbons and fibers have recently emerged as biological materials, like biocompatible 
matrices for tissue engineering [154].  Peptide nanofilaments and nanoropes were 
constructed as smart material for biosensing and signaling upon a useful 
functionalization [153]. Finally, organogels based on self-assembly were formed by 
weak non covalent interactions, thus substituting traditional covalent polymers [155]. 
We planned the production of biologically active fibrils, named catalytic amyloid 
fibrils. The idea is that of obtaining amyloid fibrils able to transform a substrate in its 
corresponding product.  
This can be achieved by genetically fusing the fibrillogenic moiety to an active 
enzyme. Two conditions must be realized: (i) the ability of the fibrillogenic partner to 
form amyloid fibrils even in the presence of the enzyme; (ii) and the ability of the 
enzymatic moiety in maintaining its activity in the amyloid-like aggregate. Considering 
the ordinate and polymeric structure of the amyloid, the catalytic amyloid fibrils could 
become a new type of noncovalent catalytic matrix.  
Few reports have been published on fusion proteins containing fibrillogenic moieties. 
Serio et al. fused the green fluorescence protein (GFP) to the fibrillogenic domain of 
the yeast Sup 35 protein and found fibrillar structures associated to green 
fluorescence [157]. Baxa et al. fused four different enzymes to the Ure2p 
amyloidogenic protein from S. Cerevisiae, with the aim to explore the role of the 
protein context on the fibrillogenic behaviour of Ure2p. They found that, while the 
Ure2p fibrillogenic behaviour varied when linked to different enzymes, in amyloid-like 
filaments the activity of the appended enzyme was found to be reduced [156]. Finally,  
designed amyloid-like fibrils generated by the well-characterized enzyme RNase A 
were found to contain native-like molecules capable of enzymatic activity [158].  
This opens the way to the construction of new amyloid-based matrices with unique 
mechanical and biological properties, having the amyloid fibrils a mechanical strength 
and resistance comparable to those of the steel [159], and being protease and 
detergent resistant. 
Recent studies demonstrated that amyloid fibrils of bacteria, fungi, insects, 
invertebrates and humans are associated to various activity (functional amyloid), [49, 
61], being able to promote different reactions without any associated toxicity. 
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AIM OF STUDY 
 
The aims of my research activity were the following:  
 
• construction, isolation and characterisation of a recombinant form of the 
fibrillogenic domain of ApoA-I, a natively unfolded polypeptide corresponding 
to residues 1-93, responsible for fibril formation in vivo;  
• definition of the fibrillogenic potential of the ApoA-I domain by conformational 
analyses; 
• construction, isolation and characterisation of 8 recombinant mutated versions 
of the fibrillogenic polypeptide, associated to amyloidosis; 
• analyses on conformational dinamics and stability of plant cystatins, as model 
proteins to study the fibrillogenic process of human cystatins associated to 
amyloidosis; 
• use of fibrillar polymers to generate catalytic fibrils for biotechnological 
applications. 
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METHODS 
 
1. Molecular cloning  
Restriction endonucleases were purchased from New England Biolabs (Beverly, 
MA). Reagents for molecular cloning were from Promega (Madison, WI).  
 
2. Bacterial Strains 
Escherichia coli strains BL21(DE3) and JM 109 (purchased from EMD Biosciences, 
Inc., Novagen Brand, Madison, WI) were used. 
 
3. Vectors 
The pGEX-4T-3 expression vector (Amersham Biosciences, Uppsala, Sweden) (Fig. 
7), was used to transform E. coli strains [160]. The pGEX plasmids are designed to 
allow inducible, high level intracellular expression of genes, or gene fragments, as 
fusions with Schistosoma japonicum glutathione S-transferase (GST). pGEX-4T-3 
expression vector contains a tac promoter for chemical induction; a multiple cloning 
site (MCS); an internal lac Iq gene compatible to any E. coli  host; a thrombin 
protease recognition site for cleaving the fusion protein.  
 
 
Fig. 7: Structural organisation of pGEX-4T-3 expression vector (Amersham 
Biosciences, Uppsala, Sweden) 
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4. Antibiotics 
Ampicillin (100 mg/ml) was solubilized in deionized water, filter sterilized and stored 
at –20°C until use. Ampicillin was used at 100 µg/ml in both solid and liquid media.  
l) 
as added to liquid or solid 2x YT-G medium to a final concentration of 100 μg/ml. 
ies. Antibodies 
were diluted in PBS buffer, containing 0.1% Tween 20 and 1% BSA. 
 used as a mixture of 
rotease inhibitors, according to manufacturer’s instruction. 
 100 μl) and plated on LB 
gar containing ampicillin (final concentration 100 μg/ml). 
verse primer b (R, b in 
fx enzyme from Pyrococcus (5 
Biosystems (Foster City, CA) apparatus, 
 
5. Solid and liquid media for bacterial strains 
LB (Luria-Bertani) and 2x YT-G media were prepared as described by Sambrook and 
Russel [161]. To prepare a solid medium, 1.2–1.5 g of agar were added to 100 ml 
medium. Culture media were supplemented with antibiotic. Ampicillin (100 mg/m
w
 
6. Antibodies 
The antibodies used in the current study were the following: anti-human ApoA-I 
polyclonal antibodies (Dako-Cytomation, Glostrup, Denmark, dilution 1:500); Anti-
GST polyclonal antibodies (General Electric Company, Fairfield, CT, dilution 1:1000), 
as primary antibodies. Horseradish peroxidase-conjugated goat anti-rabbit 
immunoglobulin antibodies (Pierce, Rockford, IL, dilution 1:10000); alkaline 
phosphatase-conjugated rabbit anti-goat IgG immunoglobulin antibodies (General 
Electric Company, Fairfield, dilution 1:3000), as secondary antibod
 
7. Protease inhibitors 
Complete Protease Inhibitor Cocktail Tablet (Roche) was
p
 
8. Preparation of Bacterial Competent Cells and Transformation   
Single clones of BL21 (DE3) E. coli strain, grown at 37ºC in LB agar, were inoculated 
into 5 ml of LB medium. Cells were incubated at 37ºC on a shaker, and grown up to 
O.D.600 = 0.6. Cells (1.5 ml) were then incubated 10 min at 0ºC, and collected by 
centrifugation at 5000 rpm for 5 min at 4ºC. Cell pellet was dissolved in 750 µl of ice-
cold 50 mM CaCl2, and incubated for 20 min at 0ºC. Cells were then centrifuged, and 
the cell pellet was dissolved in 150 µl of 50 mM CaCl2. Competent cells (150 μl) were 
transformed with plasmidic DNA and incubated 40 min at 4ºC. Heat shock was 
performed by incubating cells 2 min at 42ºC followed by 2 min at 4ºC. Following the 
addition of 1 ml of medium, cells were incubated 1 hour at 37ºC and centrifuged at 
5000 rpm for 3 min at room temperature. Medium (1 ml) was then removed and the 
cell pellet was dissolved in the remaining solution (about
a
 
9. Construction of the chimeric cDNA encoding [1-93]ApoA-I and its variants. 
The cDNA encoding fragment 1-93 of ApoA-I (denoted as [1-93]ApoA-I) was 
obtained by PCR amplification using the full length ApoA-I cDNA as a template, the 
forward primer a (denoted as F, a in Table III), and the re
Table III). EcoRI and BamHI restriction sites are underlined.  
PCR reactions were performed in a final volume of 50 μl, using 20 ng of template 
DNA. The reaction mixture contained the 2 primers (20 μM each), dNTPs (0.2 mM 
each), MgSO4 (1 mM), the amplification buffer and P
U) (Invitrogen Life Technologies, Inc., Carlsbad, CA). 
PCR was performed using an Applied 
following the procedure indicated below: 
Denaturation step:   2 min at 95º  
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Annealing:                                    2 min at 55ºC  
 III as the reverse primer. Restriction sites  are underlined; the P90 
odon is in bold. 
 
ly. Restriction sites are underlined; the mutated nucleotide sequences are 
 bold.   
Mutation Mutagenic oligonucleotides (°C)
Elongation:                    2 min at 73ºC 
for 30 cycles. The cDNA encoding fragment 1-93 of ApoA-I, carrying the mutation 
L90P([1-93]ApoA-I) was obtained by PCR amplification performed under the same 
conditions described above, using full length ApoA-I cDNA as a template, 
oligonucleotide a as the forward primer (Table III) and the mutagenic oligonucleotide, 
reported in Table
c
Tm
 
Table III: oligonucleotides used as primers in the PCR reactions performed to 
generate the [1-93]ApoA-I variants. Melting temperature (Tm) values calculated for 
each oligonucleotide are shown. (R) and (F), reverse and forward primers, 
respective
in
 
The cDNA encoding the other 7 variants of [1-93]ApoA-I, that have been expressed,  
reported in Table III, were obtained following a 2-step site-directed mutagenesis, a  
procedure reported in Fig. 8. In the first step, two PCR reactions were performed in 
parallel experiments using the following  oligonucleotides; d (see Fig. 8) was used as 
the forward mutagenic primer in combination with oligonucleotide b as the reverse 
primer, or oligonucleotide c as the reverse mutagenic primer in combination with 
oliogonucleotide a as the forward primer. In the second step, equivalent amount of 
(F, a) 5’CGCGGATCCGATGAACCCCCCCAGAG3’ 56 
Wild type 
(R, b) 5’CCGGAATTCTTACACCTCCTCCAGATCCTTG3’ 56 
(R) 5’GTCTCTGCGGCTGTCTTTGAG3’ 62 G26R 
(F) 5’GACAGCCGCAGAGACTATGTG3' 62 
(F) 5’GACAACCGGGACAGCGTGACC3’ 66 T50R 
(R) 5’GCTGTCCCGGTTGTCAAGGAG3’ 64 
(F) 5’AGCAAGCGGCGCGAACAGCTC3’ 66 L60R 
(R) 5’TTCGCGCCGCTTGCTGAAGGT3’ 64 
(F) 5’GAACAGCCCGGCCCTGTGACC3’ 68 L64P 
(R) 5’AGGGCCGGGCTGTTCGCGCAG3’ 70 
(F) 5’GATAACCCGGAAAAGGAGACA3’ 58 L75P 
(R) 5’CTTTTCCGG TATCCCAGAA3’ GT 58 
(F) 
5’CTCCACCTTCAGCAAGGTCACCTGGGATAACCTGGAAAAG3’ 75 Δ60-71/ 
insValThr 
5’ ’ 
(R) 
CTTTTCCAGGTTATCCCAGGTGACCTTGCTGAAGGTGGA3 75 
(F) 5’GGCCCTGTGACCCAGGATAACCTGGAAAAGGAG3’ 73 Δ70-72 
(R) 5’CTCCTTTTCCAGGTTATCCTGGGTCACAGGGCC3’ 73 
L90P (R) 5’CCGGAATTCTTACACCTCCTCCGGATCCTTGCT3’ 72 
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the obtained products were mixed and PCR amplified using primers a and b. 
Amplification reactions were performed as previously described. The sequence of the 
mutagenic primers is reported in Table III. All amplification products were analysed 
y 1% agarose (Promega) gel electrophoresis. b
 
 
 
PCR products were purified using a DNA purification system (Promega Biosciences 
Inc., San Luis Obispo, CA), and digested with EcoRI and BamHI restriction enzymes. 
Each amplified fragment (6 μg) was digest with 20 U of restriction enzymes for 2 
hours at 37ºC. Following the digestion, each fragment was cloned into the 
corresponding sites of the pGEX-4T-3 expression vector, downstream to the 
sequence encoding glutathione S-transferase (GST). To this purpose, the expression 
vector was previously digested with EcoRI and BamHI restriction enzymes, and 
treated with shrimp alkaline phosphatase (SAP, 20 U) (Roche Applied Science, 
Indianapolis, IN) for 15 min at 37ºC. SAP enzyme was then inactivated at 65ºC for 10 
min. Ligation was then performed using the commercial kit purchased by Promega 
final product 
2nd 
amplification 
reaction 
1st 
amplification 
reaction 
c b
a
b 
da 
Fig. 8: Schematic representation of the 2-step site-directed PCR mutagenesis
for the production of [1-93]ApoA-I variants. Restriction sites are in yellow; the
oligonucleotides c and d  harbour the mutation (M, red square) 
 
full length ApoA-I cDNA 
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Biosciences Inc. (San Luis Obispo, CA), with a 1:10 molar ratio (vector:insert DNA), 1 
mM ATP and  T4 DNA ligase (1 U) in a final volume of 10 μl. 
Following the ligation, the recombinant products were fully sequenced by MWG 
iotech, Ebersberg, Germany. Sequence analyses confirmed the expected DNA 
xpression, an aliquot of cell culture was 
moved before and after induction and analysed by polyacrylamide gel 
ng 1 mM DTT. The affinity selected proteins were then digested  with  8 U/mg 
polypeptides were assessed by mass spectrometric analyses. The polypeptides were 
B
sequences. 
 
10. Expression of the fusion protein GST-[1-93]ApoA-I and its variants. 
Single clones of E. coli BL21DE3 strain, previously transformed with one of the 
recombinant pGEX-4T-3 expression vectors and grown at 37ºC on LB agar 
containing 100 μg/ml ampicillin, were inoculated in 100 ml of 2x YT-G medium, 
containing the same antibiotic and 2% glucose. Cells were grown at 37ºC on a 
shaker up to O.D.600 = 0.6, diluted with 10 volumes of medium, inoculated in the 
same medium containing the antibiotic, and grown into a BioFlo 3000 bench top 
fermentor (New Brunswick Scientific, NY). During cell growth, pH was kept constant 
to 7.0, temperature at 37°C and shaking within the range 200-300 rpm. DOT was 
continuously monitored and the foam formation was controlled by adding the 
antifoam 204 (Sigma Aldrich co.). All operations were conducted aseptically. 
Following bacterial growth up to O.D.600 = 1, the expression of chimeric proteins was 
induced by the addition 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 2 h at 
37°C. To verify the chimeric protein e
re
electrophoresis and by Western blotting. 
 
11. Purification of recombinant [1-93]ApoA-I polypeptide and its variants. 
Bacterial cells were harvested by centrifugation at 6000 rpm for 20 min at 4ºC. Cells 
were resuspended on ice-cold PBS, containing protease inhibitors to avoid peptide 
degradation. Bacterial lysates, obtained by sonication with a Misonix (Farmingdale, 
NY) apparatus, were incubated for 30 min at 4°C in the same buffer containing 1% 
Triton X-100. Bacterial lysates were then centrifuged and the supernatant (soluble 
fraction) was fractionated by affinity chromatography on a glutathione-agarose 
column (GSTrap, GE) equilibrated in PBS, using the AKTA Purifier chromatographic 
system (Amersham, Biosciences). GST-containing species were eluted with 50 mM 
Tris-HCl at pH 8.0, containing 10 mM glutathione following the manufacturer’s 
protocol, but in the absence of DTT to avoid inhibition of thrombin enzymatic activity. 
Following the chromatography, the column was routinely washed with PBS solution 
containi
of thrombin (Sigma, St. Louis, MO) for 30 h at 4°C in the chromatography elution 
buffer. 
The proteolytic products were separated by HPLC reverse chromatography on a C8 
column (Ultrapure C8, Beckman Coulter, Fullerton, CA) with a gradient of acetonitrile 
in the presence of 0.1 % TFA (buffer B) at a flow rate of 1 ml/min, using the Perkin 
Elmer Series 200 chromatographic system (Perkin Elmer). For each variant of [1–
93]ApoA-I, optimal elution conditions were set up by varying the elution parameters.  
To avoid precipitation and/or aggregation of the polypeptides, recombinant 1-93 
polypeptides were neutralized by the addition of 2% ammonium hydroxide  and 
lyophilized. [1–93]ApoA-I polypeptides were analysed by SDS–PAGE on 15% 
acrylamide gels. For Western blot analyses, anti-human ApoA-I polyclonal antibodies  
and an anti-GST monoclonal antibodies, coupled to a chemiluminescence detection 
system (West Pico, Pierce), were used. Purity and identity of [1–93]ApoA-I 
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then lyophilized and stored at -70°C until use. For experimental purposes, 
polypeptides were dissolved in phosphate buffer at pH 7.4 and centrifuged before 
se.  
 solution was replaced by ultra pure water when protein bands were 
etected. 
miluminescent Substrate, Pierce, 
ockford, IL), using a Phosphoimager (Biorad). 
ion protein GST-[1-93]ApoA-I as a pure product to 
nti-GST antibodies (General 
lectric, CT), were carried out as previously described.  
u
 
12. Gel electrophoresis under denaturing conditions 
Gel electrophoresis under denaturing condition (SDS-PAGE) was performed as 
described by Laemmli (1970) [162] on 15% acrylamide gels. Following gel 
electrophoresis, gels were incubated for 30 min at room temperature in 20% 
isopropanol, containing 10% acetic acid and 0.1% Coomassie Brilliant Blue (Sigma, 
St. Luois, Missouri). Gels were then treated with 20% ethanol, containing 7% acetic 
acid. This
d
 
13. Western blot analyses 
For Western blot analyses, following gel electrophoresis, proteins were transferred 
overnight at 4°C to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, 
Millipore, Billarice, MA) using a 25 V electric field. Membranes were incubated in the 
blocking solution (5% BSA in PBS buffer, containing 0.1% Tween 20) at room 
temperature for 1 hour. Membranes were then washed with PBS buffer containing 
0.1% Tween 20, and incubated either with  anti-human ApoA-I polyclonal antibodies, 
dilution (1:500) or with the anti-GST monoclonal antibodies (dilution 1:1000) at room 
temperature for 1 h. Membranes were then washed with buffer and incubated on a 
shaker for 1 hour at room temperature, either with horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulin antibodies (dilution 1:10000), or with 
alkaline phosphatase-conjugated rabbit anti-goat IgG immunoglobulin antibodies 
(dilution 1:3000) as the secondary antibodies of anti-ApoA-I or anti-GST antibodies, 
respectively. Membranes were then washed with buffer. The detection of 
immunopositive species by enzyme-linked chemiluminescence (enhanced 
chemiluminescence: ECL) was performed according to the manufacturer’s 
instructions (Super Signal®West-Pico Che
R
 
14. Isolation of the fus
generate catalytic fibrils 
Following the affinity chromatography previously described, to purify to homogeneity 
the fusion protein GST-[1-93]ApoA-I, ion exchange chromatography was performed. 
The GST-containing species eluted from GSTrap were dialyzed against buffer A (3 
mM sodium phosphate, sodium acetate and glycine-HCl, pH8). Anionic exchange 
chromatography was carried out using an AKTA Purifier chromatographic system 
(GSTrap, GE), on a Resource Q column equilibrated in buffer A. The elution buffer 
was NaCl 0.5 M (buffer B). Protein species were eluted using the following 
procedure: a gradient from 0 to 37% buffer B (15 column volumes); an isocratic 
elution at 37% buffer B (10 vol.); a gradient from 37% to 55% buffer B (35 vol.); a 
gradient from 55% to 100% buffer B (5 vol.). SDS PAGE ad Western blotting 
analyses, using either anti-human ApoA-I antibodies a
E
 
15. CDNB assay 
Activity of GST-[1-93]ApoA-I fusion protein was tested using the spectroscopic  
CDNB (1-chloro-2,4-dinitrobenzene) enzymatic assay. The CDNB reaction mixtures  
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(500 μl) contained: 50 μL of 1M KH2PO4 buffer pH 6.5, 5 μL of 100 mM CDNB, 5 μL 
of 100 mM glutathione and 440 μL of distilled H2O. Upon addition of the protein to be 
tested, absorbance variations were recorded at 340 nm within 5 min and expressed 
as ΔA340/min. As a small fraction of glutathione reacts with CDNB even in the 
absence of enzyme, the amount of spontaneously formed product was determined by 
performing assays in the absence of the enzyme. The obtained ΔA340/min values 
were subtracted by the corresponding values determined in the presence of the 
nzyme.  
as expressed using the expression vector pGEX-4T-3 
R, MRC, London,  
determine protein concentration was used according to 
anufacturer’s instruction.  
ried out as described 
on of 5 μM in buffer A, at 25°C, using a Jasko J815 CD 
CDPro program pack 
) [163]. 
using an immersed thermocouple. Thermodinamic unfolding analyses were 
e
 
16. Expression and purification of recombinant GST and cystatins 
S. japonicum GST protein w
and purified according [160]. 
Mnei and oryc proteins cDNAs, provided by Dr. A. Pastore of NIM
were expressed and purified according to Spadaccini et al. [136].  
Bradford assay (Pierce) to 
m
 
17. CD spectra  
[1-93]ApoA-I far-UV circular dichroism spectra were obtained in collaboration with the 
group of Prof V. Bellotti, University of Pavia, using a Jasco J-710 spectropolarimeter 
(Great Dunmow, Essex, UK),  equipped with a temperature control system, using a 1-
mm quartz cell in the far UV range 190-250 nm. Each spectrum was the average of 
three scans with the background of the buffer solution subtracted. Measurements 
were performed at 20°C at a protein concentration of 0.3 mg/ml solubilized in 3mM 
glycine, 3 mM sodium acetate and 3 mM sodium phosphate at pH 7 (buffer A). The 
acidification or neutralization of the protein solution  were car
[102]. CD data were expressed as mean residue ellipticity (θ).  
The CD spectrum of GST and of the GST-[1–93]ApoA-I were carried out in a similar 
way at a protein concentrati
Spectrometer (Jasko corp.) 
Cystatins far-UV circular dichroism spectra were acquired using a cell of 1 mm path-
length and a Jasco J-715 spectropolarimeter (Great Dunmow, Essex, UK) equipped 
with a PTC-348WI Peltier temperature controller. The protein under test was diluted 
to a final concentration of 0.2 mg/ml either in 50 mM phosphate buffer, pH 7.0, 
containing 0.1 M sodium fluoride, or in 15 mM glycine buffer, pH 2.5 containing 0.15 
M sodium cloride. Far-UV CD spectra were obtained in the range 190-260 nm as the 
average of at least 16 scans and blank-subtracted. Spectra processing were 
obtained by using the Spectra Manager software (Jasko corp.) and the SpecPro 
program (kindly provided by dott. SR Martin from NIMR, MRC, London). The analysis 
of the secondary structure content was performed following the  programs Continll, 
Selcon3 and CDSSTR of the 
(http://lamar.colostate.edu/~sreeram/CDPro/
 
18. Thermal unfolding analyses 
Cystatins thermal unfolding was performed at 0,2 mg/ml protein concentration either 
in 50 mM phosphate buffer pH 7.0, containing 0.1 M sodium fluoride, or in 15 mM 
glycine buffer, at pH 2.5, containing 0.15 M sodium chloride The temperature was 
increased from 20°C to 90°C at a rate of 2°C/min. The CD signals were acquired at 
1°C intervals at the indicated wavelength. The sample temperature was measured 
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conducted using the Curfit program (kindly provided by dott. SR Martin from NIMR, 
MRC, London). Thermal denaturation data were fitted to the two-state model:  
Y = {IN + SNT}FN +  {IU + SUT}FU 
where T is the temperature (°C), IN and IU  represent the intercepts and SN and SU 
represent the slopes of the pre- (N) and post- (U) transition baselines, respectively. 
FN and FU are the protein fractions of the total population in the native and denatured 
state, respectively. 
Free energy values used to calculate the fractional populations were obtained from 
the modified Gibbs–Helmholtz equation  [164]. 
ΔGT = ΔHm ( 1 - T/Tm ) + ΔCp [ ( T - Tm ) – Tln( T / Tm ) ] 
where Tm and ΔHm are the midpoint melting temperature and the enthalpy at Tm, 
respectively, and ΔCp is the difference in heat capacity between the native and 
denatured states [165]. Values of ΔGT were calculated using a ΔCp value fixed at 1.4 
kcal/mol K, a reasonable value for proteins of the size of the protein under test [166] 
because of  the difficulty to define ΔCp by the analysis.  
 
19. Binding of fibrillar structures to  8-anilino-1-naphthalenesulphonate (ANS) 
The ANS(350 μM) emission fluorescence spectra in the presence of proteins were 
carried out at a protein concentration of 3 μM at 25°C in buffer A, using a LS55 
luminescence Spectrometer (PerkinElmer). ANS emission fuorescence spectra were 
recorded in the range of 400–600 nm at the excitation wavelength of 380 nm and the 
slit widths set at 5 nm. Spectra were recorded before and after acidification to pH 4 
followed by neutralization to pH 7 by adding HCl and NaOH, respectively.  
 
20. Thioflavin T assay  
[1-93]ApoA-I polypeptide (20 μM) was incubated at room temperature in buffer A at 
pH 4.0, containing 0.02% sodium azide and 15 μM Thioflavin T (ThT). When 
necessary, assays in phosphate buffer at pH 6.4 were also performed. ThT 
fluorescence emission spectra were acquired at 1 h intervals with a scan speed of  
300 nm/min, upon excitation at 450 nm.  Spectra were recorded in the range 455-600 
nm. Excitation and emission slits were set at 5 nm and 10 nm, respectively. The 
fluorescence intensity values emitted at 482 nm were plotted as a function of time. 
ThT fluorescence emission spectra in the presence of GST or of the GST-[1–93] 
ApoA-I fusion protein were carried out in a similar way at a protein concentration of 
10 μM, 25°C in 3 mM glycine, 3 mM sodium acetate, and 3 mM sodium phosphate 
(buffer A) at pH 6.4. 
Cystatins were incubated at 86°C at a concentration of 100 μM in 15 mM glycine 
buffer, pH 2.5 containing 0.15 M sodium cloride. 7 μL were withdrawn every hour and 
added to 800 μl of 25 mM phosphate buffer, pH 7.5, containing 20 μM ThT. 
Immediately after mixing, ThT fluorescence emission spectra were acquired using a 
SPEX FluoroMax fluorimeter (Jasko corp.) upon excitation at 442 nm, in the range 
455-600 nm. Excitation and emission slits were set at 5 mm and 7 mm, respectively. 
 
21. Congo Red assay 
Proteins  were incubated for about 60 h at room temperature in buffer A or at pH 4.0 
or  at pH 7.0. The protein was than diluted to 100μg/ml in PBS and the spectrum 
acquired (spectrum B). Congo Red was then added to a final concentration of  20 μM 
(14 μg/ml); upon 15 min equilibration at room temperature, the spectrum of Congo 
Red was acquired (spectrum A). The spectrum of Congo Red (20 μM) in PBS in the 
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absence of protein was also acquired, as a control (spectrum C). Spectra were 
acquired in the range 400-600 nm using a Cary 50 Bio UV-visible spectrophotometer 
(Varian). The ratio of Congo Red (μM) to protein (μg/ml) was about 1:5 according to 
Klunk WE et al [176]. Differential spectra of the complex Congo Red-protein were 
obtained by subtracting spectra B and C from spectrum A, using the CaryWinUV 
software (Varian corp.). 
 
22. Gel-filtration chromatography. 
[1-93]ApoA-I (0,2 mg/ml) was incubated for 72 h at room temperature in buffer A at 
pH 4.0 or pH 7.0. Gel-filtration chromatography was performed on a Superdex G-75 
column (GE) equilibrated in buffer A at pH 7, containing 0.15 M sodium chloride. 
Cystatins were incubated at 86 °C, or 50 °C, for 0, 3, 6 h at a protein concentration of  
100 μM in 15 mM glycine buffer, pH 2.5, containing 0.15 M sodium chloride. 
Following incubation, gel-filtration chromatography was performed on a Superdex G-
75 column (GE) equilibrated in 15 mM sodium phosphate at pH 7, containing 0.15 M 
sodium chloride. 
 
23. Atomic force microscopy (AFM) 
AFM analyses were performed in the laboratory of Prof. A. Gliozzi, University of 
Genova. AFM analyses of the cystatin mnei, were performed in London. The protein 
was incubated for 7 h at 85 ºC at 1 mg/ml in a 15 mM glycine buffer pH 2.5 
containing 0.15 M NaCl. Solutions were then diluted 20 times and incubated on a 
freshly cleaved mica surface. Images were acquired using a Nikon eclipsete 2000U 
microscope and a Nanowizard AFM (JPK instruments) system. An Olympus BL150 
cantilever (30 x 50 µm, 0.03 N/m, Olympus, Japan) at a frequency of 8.3 KHz was 
used.   
 
24. Bioinformatic tools  
Protein sequences were processed using the  ProtParam 
(http://www.expasy.ch/tools/protparam.html) software for the calculation of protein 
instability index [167]. Chou and Fasman algorithm [168] from Prot Scale 
(http://www.expasy.ch/cgi-bin/protscale.pl) was used to predict the propensity to 
generate  β-sheet secondary structure. Both ProtParam and Prot Scale are available 
on the ExPASy Server (http://www.expasy.ch) [169]. Tango algorithm [62] from 
DisEMBL (http://dis.embl.de/) [170]  was used to predict the aggregation propensity 
of proteins and peptides. For Tango (http://tango.crg.es/) analyses, pH values were 
varied,  while temperature was kept constant at  25°C, ionic strength at 0.01M, in the 
absence of TFE as a cosolvent. Waltz algorithm [171] (http://switpc7.vub.ac.be/cgi-
bin/submit.cgi) was also used to predict amyloidogenic regions in protein sequences 
at neutral or acidic pH values. 
Protein structure images were obtained from PDB 
(http://www.rcsb.org/pdb/home/home.do) using the Pymol program 
(http://pymol.sourceforge.net/) [172]. Sequence alignments were performed using 
ClustalW (http://www.ebi.ac.uk/Tools/clustalw/ index.html) [173]. 
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RESULTS 
 
1.  Structural and functional studies on the fibrillogenic 
domain of ApoA-I 
 
1.1  Expression and isolation of recombinant [1–93]ApoA-I as a stable product 
The lack of suitable amounts of the amyloidogenìc domain of ApoA-I from natural 
sources has impaired so far the understanding of the molecular mechanism of ApoA-
I related amyloidosis. 
Amyloidogenìc ApoA-I polypeptide, corresponding to the 93-residue N-terminal 
region of ApoA-I, and denoted as [1–93]ApoA-I, is a natively unfolded protein [102]. 
Attempts to express a recombinant form of the polypeptide, either in prokaryotic or 
eukaryotic cells, had failed so far, probably due to the rapid intracellular digestion of 
the unstructured product, and the high instability of the polypeptide. Recently, we 
succeeded in the production of a recombinant form of [1–93]ApoA-I [174]. The 
polypeptide was expressed in bacterial cells, following an experimental strategy 
aimed at reducing the intracellular degradation during its production [174].  
The following strategy was used. The polypeptide was  expressed as a chimeric 
protein, obtained by fusing the 93-residue polypeptide to the enzyme glutathione S-
transferase (GST). 
The cDNA encoding fragment 1–93 of ApoA-I  was obtained by PCR amplification 
using full length ApoA-I cDNA as a template and suitable oligonucleotides to amplify 
the 1-93 sequence. Restriction sites for EcoRI and BamHI were also inserted to 
clone the amplified cDNA in pGEX-4T-3 expression vector, downstream to the 
sequence encoding glutathione S-transferase (GST) [174]. Competent bacterial cells 
were transformed with pGEX-4T-3 vector carrying the GST-[1–93]ApoA-I construct 
and induced to express the recombinant protein. 
Analyses by SDS–PAGE of bacterial lysates showed the presence of a major protein 
species in IPTG-induced cells (Fig. 9A, lane 3) with a molecular mass of about 36 
kDa, as expected for the chimeric product. This product was specifically recognised 
by anti-ApoA-I antibodies (Fig. 9B, lane 3). In this sample, additional immunopositive 
species with a molecular mass lower than that of the chimeric protein were also 
present (see below). 
By affinity chromatography on a  GSH-agarose affinity column, the GST-containing 
species were selected.  In Fig. 10, the affinity chromatography elution profile is 
showed. Analyses by SDS–PAGE (Fig. 9A, lane 4) confirmed that the selected 
proteins contained exclusively species immunopositive to anti-ApoA-I antibodies (Fig. 
9B, lane 4). Coomassie-stained protein bands, corresponding to the immunopositive 
species, were excised from the gel and digested in situ with trypsin. The resulting 
peptide mixtures were analysed directly by MALDI mass spectrometry in the 
laboratory of Prof. P. Pucci of the University of Naples. The analyses showed that the 
main product was indeed the GST-[1–93]ApoA-I chimeric protein (indicated in Fig. 9 
by an arrow). In addition, minor species corresponding to C-terminal truncated 
chimeric products were also identified. 
The [1–93]ApoA-I moiety was then released from the chimeric protein by targeted 
proteolysis, making use of a unique cleavage site for thrombin positioned between 
the GST and the [1–93]ApoA-I coding sequences. The proteolysis mixture, analyzed  
  35
 
 
Fig. 9: Analysis by SDS–PAGE of recombinant [1-93]ApoA-I. (A) Coomassie 
staining; (B) Western blotting. 
Lane 1, native [1–93]ApoA-I extracted from ex vivo fibrils; 
lanes 2 and 3, soluble fractions prepared from non-induced bacterial cells 
(lane 2), or  from induced cells (lane 3);  
lane 4, GST-containing proteins selected by affinity chromatography; 
lane 5, thrombin proteolytic products; 
lane 6, HPLC purified [1–93]ApoA-I.  
The arrow indicates the full length GST-[1-93]ApoA-I fusion protein. 
 
Fig. 10: Affinity chromatography profile of  GST-containing proteins selected 
by a GSTrap column. The recorded absorbance at 280 nm is shown in black;
the elution gradient (%B)  is shown in orange.           
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by SDS–PAGE and Western blotting (Fig. 9A and B, lane 5), was resolved by 
reverse-phase HPLC using a gradient of acetonitrile in TFA, as described in the 
Methods section.  
The eluted fractions were immediately neutralized by the addition of small amount of 
ammonium hydroxide. The reverse-phase HPLC profile, shown in Fig. 11, showed 
two well resolved peaks. The minor one (eluted with 48% of acetonitrile and indicated 
by an arrow)  was found to contain a homogeneous protein with the same 
electrophoretic mobility of the native fibrillogenic polypeptide. This species was 
recognised by anti-ApoA-I antibodies (Fig. 9A and B, lane 6).  
 
 
 
Fig. 11: RP-HPLC profile of [1-93]ApoA-I polypeptide. The absorbance 
recorded at 280 nm is shown in black; the acetonitrile gradient (%B)  is 
shown in orange. The arrow indicates the peak corresponding to the 
fibrillogenic polypeptide. 
An aliquot of this product was analysed by electrospray mass spectrometry (ESMS). 
The molecular mass of 10863.8 ± 0.1 Da was calculated and found to perfectly match 
the expected mass value of [1–93]ApoA-I, with the addition of two extra residues (Gly 
and Ser). These extra amino acids are in fact present at  the N-terminal end of the 
polypeptide  and originate from the chimeric construct following thrombin cleavage.  
Using this procedure we were able to isolate a pure recombinant form of [1–93]ApoA-
I with a recovery of about 1mg/L of bacterial culture.  
Having established a suitable protocol for cloning, expressing and purifying a 
recombinant form of the amyloidogenic polypeptide of ApoA-I, the way was open to 
study the self-association process of the amyloidogenìc polypeptide. 
 
1.2  Characterisation of [1–93]ApoA-I  
A partial characterisation of natural [1–93]ApoA-I polypeptide, extracted from fibrils 
obtained from patients affected by a severe form of cardiac ApoA-I amyloidosis, had 
shown that the 1-93 N-terminal portion of ApoA-I is intrinsically amyloidogenic in a 
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physiological environment. The natural 1-93 amyloidogenic fragment was found to be 
able to aggregate in acidic conditions (pH 4.0) generating amyloid  fibrils [102]. 
In collaboration with the research group of Prof. V. Bellotti of the University of Pavia, 
we analysed the ability of the recombinant [1–93]ApoA-I polypeptide to generate 
fibrils as its natural counterpart. The fibril formation propensity of [1–93]ApoA-I 
polypeptide was then investigated  using a multidisciplinary approach.  
 
1.2.1  In silico analysis 
The aggregation propensity of [1–93]ApoA-I polypeptide was first examined using 
algorithms proposed by some authors. The instability index  of [1–93]ApoA-I (46.67), 
calculated using Prot Param [167] allowed us to classify the polypeptide as unstable. 
The propensity of [1–93]ApoA-I to generate fibrils was first analysed using the Tango 
algorithm defined by L.Serrano et al. [62]. 
Tango analyses of polypeptide were performed at 25°C, at 0.01 M ionic strength in 
the  absence of co-solvents. Tango algorithm predicted a very high propensity of [1–
93]ApoA-I to generate β-crossed aggregated structures at pH 7.0 and 4.0. 
In Fig. 12, the aggregation value (AGG), that describes the overall protein propensity 
to aggregate, is reported. The aggregation propensity was found to be higher at pH 
4.0 than at pH 7.0, according to the experimental data previously reported for natural 
[1–93]ApoA-I polypeptide [102]. The propensity to generate β-cross aggregates is 
localised mainly within the region comprised from residue 13 and residue 25 at both 
pH values (Fig. 12). No propensity to aggregate in a helical conformation was instead 
predicted by Tango. 
 
 
Fig 12: The aggregation propensity of [1-93]ApoA-I residues predicted by the 
Tango algorithm. The overall aggregation score (parameter AGG), determined by 
the algorithm  for the whole polypeptide at pH 7.0 and 4.0 is shown. 
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The 13-25 region was predicted to be prone to aggregation also using the Waltz 
algorithm [171], even if further aggregating regions were also identified, due to the 
lower specificity of this algorithm (data not shown). Finally, the region 13-25 was 
predicted to have high tendency to form β-sheet based structures also using the 
algorithm of Chou and Fasman [168]. 
Interestingly, the C-terminal region, for which no aggregation propensity was 
detected using TANGO algorithm, was found to be unaccessible to proteases, both 
under native conditions and in the presence of a cosolvent (20%TFE), as 
demonstrated by the group of Prof. P. Pucci of the University of Naples by using 
limited proteolysis coupled to mass spectrometric analyses [174]. 
 
1.2.2  Spectroscopic characterisation of [1-93]ApoA-I 
The conformational characterisation of [1–93]ApoA-I was performed by spectroscopic 
(a) and spectrofluorimetric (b) analyses described below. 
 
a.  CD spectroscopic analyses   
CD spectroscopic analyses were performed in collaboration with the group of Prof. V. 
Bellotti, University of Pavia. The overall far-UV CD spectrum of [1-93]ApoA-I at 
neutral pH is shown in Fig 13A. The minimum at 203 nm indicated that the peptide is 
highly unstructured under these conditions, which is in line with the in silico  
characterisation. A  marked change in the spectrum was observed at pH 4.0, with a 
shift of the major minimum from 203 nm to 208 nm. This was accompanied by a 
considerable increase in ellipticity at 222 nm and 190 nm. Such spectral changes are 
consistent with a transition to a helical structure  at pH 4.0, and are in good 
agreement with the behaviour of the natural [1-93]ApoA-I polypeptide[102]. 
Moreover, as described for the natural polypeptide, when the protein was left at pH 
4.0 we observed the decay of the CD signal during protein aggregation and 
precipitation.  
Interestingly, the pH-induced changes in the spectrum were reversed when the pH 
was neutralised within a few seconds (Fig. 13A). 
Fig. 13B reports the time dependence of the CD spectra changes induced by acidic 
conditions. After 60 min incubation at pH 4.0, we observed the disappearance of the 
minimum at 222 nm and the persistence of a second minimum at 205 nm, which is 
suggestive of a transition to a β-sheet structure. 
From these data, a complex and multistep intriguing aggregation pathway emerges 
for [1–93]ApoA-I. Major conformational rearrangements are involved and different  
intermediate species with own structural characteristics are generated during the 
aggregation process. During this pathway, the fibrillogenic polypeptide assumes a 
random coil structure at neutral pH, shifts into an unstable helical conformation at 
acidic pH and then aggregates into a β-sheet-based structure.  
 
b.  Spectrofluorimetric analyses 
To further investigate the transient helical conformer, which represents a key 
intermediate in the fibrillogenic pathway, we used spectrofluorimetric techniques to 
analyse  the binding of the apolar dye ANS to [1-93]ApoA-I.  
The ANS fluorescence dye is frequently used to detect  partially folded, molten 
globule-like intermediate states of globular proteins. This hydrophobic dye binds to  
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Fig. 13: Spectroscopic analyses of [1–93]ApoA-I. (A) pH-induced transition of 
[1–93]ApoA-I secondary structure monitored by far-UV CD. Spectra were 
recorded at pH 7 (blue lines), pH 4 (orange lines), and upon neutralisation to 
pH 7 (red lines). (B) Time dependence of the induction of secondary structure 
of [1–93]ApoA-I at pH 4. The far-UV CD spectra were recorded at pH 7 and 
after a pH shift to pH 4 at the indicated time intervals. After about 60 min of 
incubation at pH 4, the CD spectra indicated  the transition to a β-sheet 
structure. (C) pH-induced binding of ANS to [1–93]ApoA-I. Symbols are as in 
(A). ANS emission fluorescence spectra were recorded in the range of 400–
600 nm, at the excitation wavelength of 395 nm, with the slit widths set at 5 
nm. Spectra of the free dye at pH 7 and 4 are shown in the inset. 
A B 
C 
solvent-exposed hydrophobic surfaces of polypeptide chains. Folded or unfolded 
states of proteins exhibit very weak binding affinity for ANS, whereas conformational 
states with clusters of exposed hydrophobic groups have a much higher affinity, 
making this dye a suitable marker for partially folded protein states. Upon binding, 
ANS  induces a characteristic enhancement of  fluorescence intensity and a blue shift 
of the emission wavelength [17].  
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In the case of [1-93]ApoA-I, binding of ANS to the protein at pH 7.0 led to a slight 
blue shift from 515 to 489 nm, without any increase in fluorescence emission (Fig. 
13C). The acidification of the pH, however, led to a substantial change of ANS 
fluorescence, reflecting the pH-induced transformation into a partially folded 
conformation. At pH 4.0, the ANS maximum emission shifted to 477 nm with a 
considerable increase in fluorescence intensity (Fig. 13C), consistent with the 
behaviour previously ascribed to proteins in a molten globule state [17]. When the pH 
was returned to pH 7.0, the reversibility of the ANS–ApoA-I polypeptide complex was 
found to be consistent with the data obtained by the CD spectra. In the inset of Fig. 
13C the pH dependence of the fluorescence intensity of the free dye  is shown for 
comparison. 
 
The data obtained by CD and fluorescence experiments have shown that a pH shift 
from 7.0 to 4.0 induces the formation of a helical conformer, that displays a CD 
spectrum consistent with a predominant α-helical structure and the ability to bind 
ANS in a manner similar to that observed for molten globule states. This interaction is 
abolished when pH was returned to pH 7.0. The conversion of the protein from a 
random coil structure to a helical/molten globule state at pH 4.0 is a key step in the 
fibrillogenic pathway. Noteworthy, a helical conformer was identified as an 
intermediate species in the fibrillogenic pathway of diverse proteins [175]. This 
intermediate displays a strong propensity to oligomerise. For this reason,  attempts to 
further analyse this intermediate species of the fibrillogenic pathway of some 
amyloidogenic proteins failed, due to the rapid formation of insoluble species. 
 
1.3  Analyses of [1-93]ApoA-I fibrillar structure 
We analysed the presence of a β-sheet-based structure upon long exposure of [1-
93]ApoA-I to acidic conditions. To detect the presence of  β-cross structure, the 
typical motif of fibrillar structures, we performed colorimetric assays with Congo Red 
as well as fluorimetric assays with Thioflavin T. Both assays are commonly used to 
detect the presence of amyloid fibrils.   
 
1.3.1  Congo Red assays 
The ability of amyloid proteins to induce a shift in the spectrum of Congo Red (CR) 
depends on the protein aggregation state. Upon binding of Congo Red to ordered 
aggregates, the absorbance maximum of the dye undergoes a red shift from 490 to                     
540 nm [176]. In addition to this effect, many amyloid fibrils show inherent light 
scattering properties [177].  
We incubated [1-93]ApoA-I at 1 mg/ml in buffer A (3 mM glycine, 3 mM sodium 
acetate and 3 mM sodium phosphate) at pH 7.0 or pH 4.0.  After 3 days, the Congo 
Red assay was performed.  
Spectra of [1–93]ApoA-I (100 μg/ml final concentration) and CR (20 μM) were 
recorded separately (green and blue lines, respectively, for [1-93]ApoA-I 
preincubated at pH 4.0, Fig. 14A, or at pH 7.0, Fig 14B). Congo Red (20 μM final 
concentration) was then added to the protein solution and incubated 15 min to allow 
the dye to bind to fibrillar structures (Fig. 14A and B, orange lines). The spectrum of 
the complex Congo Red-protein was then recorded. Differential spectra were 
obtained by subtracting the spectrum of the dye and that of the protein alone from the 
spectrum of the complex. The results of these experiments are shown in Fig. 14.  
A differential spectrum was obtained when CR was added to the polypeptide 
previously incubated for 72 h at pH 4.0 (see Fig.14 C, red line). This spectrum 
  41
showed the typical red shift described above. No spectral differences were detected 
when the polypeptide was preincubated at pH 7.0 (see Fig.14 C grey line). This is 
suggestive of a specific interaction of the dye with ordered β-cross structures, 
generated during the incubation at pH 4.0. 
 
 
 
Fig. 14: Congo Red spectra of [1-93]ApoA-I pre-incubated for 72 h at pH 4.0 (A) 
or at pH 7.0 (B). The spectra of the proteins in the presence of Congo Red are 
in orange; the spectra obtained with proteins alone are in green; those of Congo 
Red are in blue. (C) The differential spectra obtained by subtracting the spectra
of the protein alone and of Congo Red alone from the spectrum of the protein in 
the presence of Congo Red at pH 4.0 (red line) or pH 7.0 (gray line). 
A B 
C 
1.3.2  ThT assays 
In spite of a still unknown binding mechanism, Thioflavin T (ThT) is able to bind 
selectively to amyloid fibrillar structures, and to undergo characteristic spectral 
changes upon binding to amyloid fibrils [178] These changes consist of a shift from 
438 nm to 482 nm of the fluorescence emission major maximum, accompanied by a 
significant increase of fluorescence up to 80 fold [179].  
ThT assays were performed to monitor the formation of fibrils by [1-93]ApoA-I at pH 
4.0 and 6.4. The protein (2.5 μM) was incubated up to 300 h in phosphate buffer at 
pH 6.4, containing 0.02% sodium azide, in the presence of 15 μM ThT. In a parallel 
experiment, the protein (20 μM) was incubated in 10 mM in glycine buffer at pH 4.0 
with ThT 15 μM. ThT fluorescence emission at 482 nm was measured during [1-
93]ApoA-I incubation every hour.  
  42
Figure 15 shows the time-course of ThT fluorescence emission in the presence of  
[1-93]ApoA-I. An increase in the ThT fluorescence emission was detected at both pH 
values, with the characteristic sigmoidal shape suggestive of a cooperative 
phenomenon. The midpoint of the transition was calculated to be at about 120 h of 
incubation at pH 4.0,  and at about 225 h of incubation at pH 6.4. This indicated that 
typical polymeric β-cross structure were generated in both conditions, but an acidic 
environment and high protein concentrations favour the polymer formation. 
This is in line with the results published by Prof V. Bellotti [102], who demonstrated 
that the natural polypeptide is able to form fibrils at pH 4.0, whereas at pH 7.0 fibril 
formation required much longer times.  
 
 
 
Fig 15: The kinetics of ThT (15 μM) emission fluorescence at 482 nm in the 
presence of [1-93]ApoA-I. Aggregation was monitored at a protein concentration 
of 2.5 μM, at 37°C, in 12 mM phosphate buffer pH 6.4 (green squares) or in 
buffer A at pH 4.0 (red circles).  
Taken together, the above reported results revealed that at pH 4 [1-93]ApoA-I 
converts rapidly from random coil to an unstable intermediate with a helical molten 
globule state, able to bind ANS. The polypeptide than aggregates into a β-sheet-
based polymeric structure, having amyloid-like features and the ability to bind specific 
dyes such as Congo Red and Thioflavin T.  
 
1.4  Analysis of the aggregation state 
Analyses of the aggregated species generated by [1-93]ApoA-I were then carried out 
by gel-filtration chromatography and AFM. 
 
1.4.1  Analyses by gel-filtration chromatography 
The oligomeric state of [1-93]ApoA-I polypeptide was analysed by gel-filtration 
chromatography. Fig. 16 shows the chromatographic profile of [1-93]ApoA-I, 
determined for the non incubated protein, and for the protein incubated for 3 days at 
pH 6.4 (Fig. 16A). The profiles obtained at pH 4.0, are shown in Fig. 16B.  
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The non incubated [1-93]ApoA-I sample was eluted at an elution volume consistent 
with a dimeric species (Fig 16A, black line). After three days of incubation at pH 6.4 
(Fig. 16A orange line) about 80% of the protein was recovered from the column, as 
about 20% of insoluble species was generated and removed by centrifugation prior to 
be analysed. Trace amounts of  species with a molecular mass consistent with a 
monomeric species  were also present (arrow in Fig. 16A) 
These results indicated that the polypeptide spontaneously associates generating 
dimers. When [1-93]ApoA-I was analyzed after incubation at pH 4.0 (Fig. 16B, 
orange line), a lower amount of the dimeric species was observed when compared to 
the profile obtained with non incubated [1-93]ApoA-I, suggesting that further protein 
aggregation and/or precipitation occurred,  generating high molecular weight species 
that are not eluted from the column.  
 
 
Fig 16: (A) Gel-filtration chromatographic profiles of non incubated (black) or
incubated (orange) [1-93]ApoA-I at pH 6.4. The arrow indicates the molecular 
species eluted as a monomer. (B) Chromatographic profiles of non incubated
(black) or incubated (orange) [1-93]ApoA-I at pH 4.0. Asterisks indicate the 
elution volumes of BSA, α-amylase and cytochrome c used as standars for 
column calibration.
B 
A 
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1.4.2  Analyses by electron microscopy and atomic force microscopy 
The data described in this paragraph have been collected by Prof. A. Gliozzi of the 
University of Genova, which collaborates with our group as an expert of microscopy 
techniques. I included these data in my thesis in that they are part of the analysis of  
[1-93] ApoA-I fibrils.  
Fibrils generated by [1–93]ApoA-I  incubated at pH 4.0 were morphologically 
analysed. Fig. 17A shows an electron microscopy image obtained upon incubation of 
recombinant [1–93]ApoA-I under conditions that induce fibrils formation. A nest of 
narrow protofilaments and well defined fibrils of [1-93]ApoA-I were detectable after 
72-90 hours of incubation, consistently with the results obtained with the natural 
polypeptide [103]. Images obtained by AFM are presented in Fig. 17B. The images 
clearly indicated  that fibrillar structures with the typical amyloid morphology coexist 
with globular aggregates. The heights of protofilaments and mature fibrils from the 
AFM images were calculated to be  0.8±0.3 nm and 2.4±0.6 nm, respectively, values 
similar to those measured for the natural fibrillogenic polypeptide [103].   
 
 
 
A B 
Fig 17: Electron microscopy image (A) and AFM image (B) of [193]Apo A-I  fibrils
 
In conclusions, the data obtained from gel-filtration and microscopy clearly showed 
that [1–93]ApoA-I has a high propensity to form multimeric aggregates, generating 
typical amyloid fibrils.  
 
2.  [1–93]ApoA-I variants associated to amyloidosis 
 
2.1 Expression and isolation of recombinant [1–93]ApoA-I variants 
The experimental strategy to produce the fibrillogenic [1–93]ApoA-I as a recombinant 
protein can be successfully used to produce the mutated versions of [1–93]ApoA-I.  
As discussed above, 8 mutations in the N-terminal domain of ApoA-I (called “internal” 
mutations as they are located within the fibrillogenic domain) have been 
demonstrated so far to be associated to amyloid pathologies [84]. Following the 
protocol set up for [1-93]ApoA-I, we planned to express and isolate to homogeneity 
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the 8 mutant versions of [1-93]ApoA-I polypeptide, thus generating the complete 
panel of variants of the 93-residue ApoA-I fibrillogenic polypeptides. Six of them 
harbour a single residue substitution (mutants G26R, T50R, L60R, L64P, L75P and 
L90P), whereas two mutants harbour a deletion at sequence 70-72 and 60-71, 
respectively (in the latter case the deleted sequence is replaced by VT) [84]. In order 
to generate the complete panel of the fibrillogenic polypeptide variants, we mutated, 
accordingly to the strategy described in details in the Methods section, the cDNA 
encoding [1-93]ApoA-I. In Table IV (see below) the list of these mutations are shown. 
Each mutated DNA sequence, encoding the corresponding variant, was obtained by 
PCR site-directed mutagenesis of the original sequence using suitable primers 
designed to introduce base substitutions, base deletions or insertions, accordingly.  
It has to be underlined that the production of recombinant forms of the polypeptide 
variants is essential to produce sufficient protein amount to perform studies on the 
effects of each mutation on the polypeptide stability and propensity to aggregation. 
No attempts to express these polypeptides as recombinant proteins were previously 
made. 
Variants of  [1–93]ApoA-I were expressed in bacterial cells following the same 
experimental strategy used to produce  the [1–93]ApoA-I polypeptide. Polypeptides 
were all expressed as chimeric proteins, obtained by fusing each 93-residue 
polypeptide to glutathione S-transferase (GST).  
Analyses by SDS–PAGE of bacterial lysates were performed to confirm the 
expression of the recombinant proteins. In all cases, a major protein species of about 
36 kDa, i.e. the molecular mass expected for the chimeric product, specifically 
recognised by anti-ApoA-I antibodies, was identified (not shown). Each chimeric 
product was isolated from  bacterial lysates using the GST affinity chromatography. 
Polypeptides were then released by the chimeric construct by  targeted proteolysis 
with thrombin protease. The proteolytic products were resolved by reverse-phase 
HPLC. Particular attention was paid to choose experimental conditions that avoid 
precipitation and/or aggregation of the recombinant polypeptides. To isolate each 
variant, an optimisation of the purification procedure set up for [1–93]ApoA-I has 
been necessary.  
In Fig.18, the HPLC profiles (black lines) obtained for each ApoA-I derived 
amyloidogenìc variant is shown. The orange lines indicate the elution gradients used 
to isolate the final products.  
Protein fractions were then analyzed by SDS-PAGE and Western blot analyses (Fig. 
18A and B, respectively). The results demonstrated that the  peak indicated by an 
arrow in each chromatogram contains a pure protein species with the same 
electrophoretic mobility  of the native fibrillogenic polypeptide (Fig. 18A). These 
polypeptides were  recognized by anti-ApoA-I antibodies (Fig. 18B).  
An aliquot of the isolated polypeptides  was analysed by electrospray mass 
spectrometry (ESMS) by the group of Prof. P. Pucci, University of Naples. The 
molecular mass  measured for each recombinant variant is listed in Table IV and 
found to perfectly match the mass value expected for each [1–93]ApoA-I variant. 
Furthermore, these analyses indicated than the isolated products were 
homogeneous (>90% purity). 
In Table IV, the amount of pure recombinant products, expressed as mg of 
recombinant product  obtained from 1 L of bacterial culture, is also reported. Using 
this procedure, we were able to produce recombinant homogeneous forms of the 8 
mutants of [1–93]ApoA-I polypeptide.  
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Fig 18: The chromatographic profiles obtained by RP HPLC of the 8 
recombinant variants of [1–93]ApoA-I. In orange the elution gradient is shown. 
The arrows indicate the peaks corresponding to the expected products 
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Fig. 19: Analyses by SDS-PAGE (A) and Western Blotting (B) of the proteins
isolated by RP-HPLC (Fig. 18)  
Lane 0: molecular weight markers; Lane 1: variant G26R; Lane 2: variant 
T50R; Lane 3: variant L60R; Lane 4: variant L64P; Lane 5: variant L75P; Lane 
6: variant L90P; Lane 7: variant Δ70-72; Lane 8: variant Δ60-71 ins Val/Thr 
0    1    2    3    4    5   6     7    8              1     2     3     4    5     6     7    8          
A 
kDa 
B 
[1–93]ApoA-I 
variant Molecular weight 
Final product recovery  
(mg/L of bacterial culture) 
G26R 10963.73±0.23Da 0.5 
T50R 10834.22±0.26Da 0.3 
L60R 10907.16±0.22Da 1.2 
L64P 10848.34±0.25Da 0.8 
L75P 10847.84±0.45Da 0.8 
L90P 10847.64±0.39Da 3.6 
Δ70-72 10401.57±0.19Da 0.9 
Δ60-71/ins Val-Thr 9665.58±0.22 Da 0.2 
 
Table IV: The 8 mutants of [1–93]ApoA-I are reported with an acronym indicating the 
mutational event. Their molecular mass and purification yields are indicated. 
 
2.2. Characterisation of [1–93]ApoA-I mutants 
Experiments aimed at the characterisation of the conformational state of the 8 
amyloidogenic variants of [1–93]ApoA-I, using the techniques previously used to 
analyse [1–93]ApoA-I fibrillogenesis, are presently in progress. Nevertheless, some 
preliminary results are available.  
This work is aimed at the definition of the impact of single mutations on the protein 
aggregation propensity. This study would led to define an algorithm able to correlate 
structural determinants of fibrillogenic polypeptides to their functional features.   
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Turbidimetry and CD analyses aimed at studying conformational and structural 
dynamics of mutated polypeptides are presently in progress, in collaboration with the 
group of Prof. V.Bellotti of University of Pavia. Interestingly, preliminary results, 
obtained by turbidometric analyses, indicated that almost all mutants display an 
increased aggregation propensity with respect to [1-93]ApoA-I (Fig. 20). This is in line 
with the observation that the mutated polypeptides represent the main constituents of 
amyloid deposits in affected patients. For mutants Δ60-71ins Val-Thr and L64P the 
highest aggregation propensity was determined.  
 
 
 
Fig. 20: Turbidimetric assays of the aggregation kinetics of [1–93]ApoA-I 
recombinant variants. 
Moreover, In collaboration with the group of Prof. A. Gliozzi of the University of 
Genova, AFM analyses of fibrils generated by the recombinant variants are also in 
progress. Preliminary results suggested that variants generate fibrillar structures, 
whose morphology will be analysed in details. These analyses are aimed at the 
definition of the fibrillogenic potential of pathological mutants by microscopic 
techniques.  
We hope that the integration of the results obtained from these independent 
experimental approaches will be helpful to the definition of the molecular bases of  
fibrillogenesis.  
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3. Cystatins and amyloid aggregation 
 
Plant cystatins may undergo the typical  amyloid aggregation process [123, 124]. 
Since they are able to form typical amyloid fibrils and present the conserved 
structural motif of cystatins, plant cystatins could be an interesting model to shed light 
on cystatins aggregation.  
During my research activity in London, in the Laboratory of Dr. A. Pastore at the 
Molecular Research Council (MRC), National Institute for Medical Research (NIMR), I 
studied the aggregation pathway of two plant proteins belonging to the cystatin 
superfamily: the mnei protein, a recombinant single chain monellin engineered from 
the naturally occurred double chains monellin, from Dioscoreophyllum cumminsii, 
and oryzacystatin I (oryc), a cystatin from Oryza sativa L. japonica. 
 
3.1. In silico analyses 
Single chain monellin (mnei) and oryzacistatin (oryc) sequences were aligned using 
Clustal x [173] (Fig. 21A). A comparison of their structure from NMR data (PDB 1FA3 
for mnei, [135]: PBB 1EQK for oryc, [181]) is reported in Fig. 21B using Pymol 
program [172] 
 
 
 
Fig. 21: (A) Alignment of mnei and oryc amino acidic sequences. (B) Protein 
structure superimposition: mnei (blue, PDB 1FA3) and oryc (orange, PDB 
1EQK). 
A 
B 
As shown in the alignment, the main difference concerns the N-terminal peptide of 
oryc, involved in the inhibition of cysteine proteases. This segment has no 
counterpart in mnei protein, accordingly to the finding that mnei lacks protease 
inhibitory activity.  
Moreover, the superimposition of the structures (Fig. 21B) shows further structural 
differences, i.e. the turns show different length and the C- terminal segments of the 
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two proteins span in opposite directions. In spite of these differences, the main 
elements of secondary structure are conserved. 
On the basis of the instability index, calculated using Prot Param [167], and found to 
be 26.63 for mnei and 32.73 for oryc, both proteins were classified as stable proteins. 
By contrast, when I carried out the analyses of the aggregation propensity of these 
proteins using Tango  algorithm [62], the aggregation propensity of oryc was found to 
be higher than that of mnei, both at pH 4.0 and 7.0 (data not shown). This is not in 
contrast with the observation that for natural monellin amyloid fibrils were observed 
[123, 124] as Tango algorithm predicts aggregation rather than amyloid fibril 
formation [62]. 
 
3.2  Far-UV CD analyses 
For CD analyses, proteins were tested at a concentration of 0.2 mg/ml either  in 
50 mM phosphate buffer, pH 7.0, containing 0.1 M sodium fluoride, or in 15 mM 
glycin buffer, pH 2.5, containing 0.15 M sodium cloride. Spectra were recorded in the 
range 190-260 nm. 
Far-UV CD spectra of mnei were measured at pH 2.5 and 7.0, i.e. pH values below 
the pI of the protein (Fig. 22). Spectra analysis indicated that the protein has a  high 
β−sheet content in both conditions, with a negative band at about 215 nm. Thus, no 
pH-induced conformational transition occurred. Nevertheless, at pH 2.5 the minimum 
increases in intensity, suggesting that protein aggregation and precipitation occurred, 
possibly induced by the destabilizing action of acidic pH. 
 
 
 
Fig. 22: CD spectra of mnei (blue lines) and oryc (red lines) in phosphate buffer 
at pH 7.0 (dark colours) or in glycine buffer at pH 2.5 (light colours) 
When spectra at pH 2.5 were registered at increasing temperature values from 20°C 
to 90°C, the protein was found to adopt a random coil structure over 70°C (Tm = 
66.1°C), as suggested by the disappearance of the negative band at 215 nm  and the 
presence of a strong negative band at about 200 nm (see Fig. 23A). Spectra 
deconvolution, performed using the program CDPro [163] (Fig. 23B), showed the 
increase of a random coil structure with a simultaneous decrease of the β-sheet 
structure content. The temperature induced transition from β−sheet structure to 
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random coil at pH 2.5 was found to be reversed when temperature was lowered  to 
20°C in few minutes (Fig. 24). 
 
 
 
Fig. 23: (A) temperature dependence of CD spectra changes of mnei. CD 
spectra were recorded at the indicated temperatures in glycine buffer at pH 2.5.
(B) CDPro analyses of the spectra. Values are expressed as the percentage of 
amino acid assuming a particular structure (helix = α-helix; unordered = 
disordered structure; sheet/turn = β-sheet plus β-turn) 
B
A
MNEI
MNEI
Fig. 25A shows the time dependence of CD spectra changes upon exposure of mnei 
to high temperature at pH 2.5. We incubated mnei at 86°C, i.e. 20°C above its Tm, 
and acquired CD spectra after 90 and 150 min of incubation. A decay of the CD 
signal, associated with protein aggregation and precipitation, was registered.  
Furthermore, after 150 min of incubation at 86°C and pH 2.5, the spectra showed the 
disappearance of the minimum at 200 nm and the presence of a second minimum at 
about 210 nm, that is suggestive of a transition to a β-sheet structure. when the 
protein was left at 86°C, a progressive loss of CD signal, due to further aggregation, 
was monitored by measuring the molar ellipticity at 215 nm in the time interval 90-
150 min (Fig. 25B). The decrease of CD signal likely depends on the secondary 
structure transition, as well as on protein aggregation. 
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MNEI
Fig. 24: Reversibility of the temperature-induced transition of mnei in glycine 
buffer at pH 2.5.  
Fig. 25: (A) Time-dependence of the changes in secondary structure content of 
mnei at pH 2.5. (B) The progressive loss of CD signal was monitored by 
measuring the molar ellipticity changes at 215 nm during the incubation of 
protein  at 86°C. 
B
A
MNEI
MNEI
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The oryc spectra were registered at 20°C, at pH 2.5 and 7.0, the former value being 
lower than pI, and the latter being higher. The results  (see Fig. 22) showed a lower 
content of β-sheet structure with respect to mnei. This is possibly due to the unfolded 
structure of the N-terminal segment of oryc, positioned closely to the first β-sheet, 
and to the differences in the length of the turns. By comparing the spectra at pH 7.0 
and 2.5 we concluded that no pH-induced conformational transition occurred. 
Nevertheless, at pH 2.5 the minimum decreased in intensity with respect to pH 7.0, 
at pH 2.5 when the temperature was lowered again to 20°C in few minutes 
ig. 27). 
 
suggesting that there is a gain in structure content at pH 2.5. 
The increase of temperature from 20°C to 98°C at pH 2.5 led the protein to adopt a 
random coil structure, as suggested by the presence of the strong negative band at 
about 200 nm (Fig. 26A). Spectra deconvolution with CDPro showed an increase of 
the unfolded protein content up to 80°C (Fig. 26B). Surprisingly, above 80°C, a 
recovery in helical content was observed, while  the random coil content was found to 
decrease. As also found for mnei, the temperature induced spectral changes were 
reversible 
(F
 
Fig. 26 : (A) Temperature dependence of CD spectra changes of oryc. CD 
spectra of oryc were recorded at  the indicated temperatures in glycine buffer at 
pH 2.5. A transition from β−sheet to random coil structure occurs at about 
80°C. (B) CDPro analyses of the spectra of protein includes also their turn 
content. Values are defined as in Fig. 23B. 
B
A
ORYC
ORYC
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Fig. 28A shows the far-UV CD spectra of oryc, acquired at 90°C (~20°C above  Tm) 
at times 0, 90 and 150 min of incubation in 15 mM glycine buffer pH 2.5, containing 
.15 M sodium chloride. 
 
 
0
 
 
ORYC
Fig. 27: Reversibility of the temperature induced transition of oryc in glycine
buffer at pH 2.5  
B 
A
Fig. 28: (A) Time-dependence of the changes in secondary structure content of
oryc at pH 2.5. (B) The progressive loss of CD signal was monitored by 
measuring the molar ellipticity changes at 215 nm during the protein incubation 
at 90°C. 
ORYC
ORYC
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The spectra were almost superimposable, suggesting the absence of a time-
dependent transition, or of phenomena of precipitation/aggregation at the conditions 
used. Monitoring the molar ellipticity at 215 nm from 90 min to 150 min of incubation 
in the same conditions, we found the persistence of the CD signal, which suggested 
that no protein aggregation and precipitation occurred (Fig. 28B). 
 
3.3  Heat-denaturation experiments 
To  perform heat-denaturation experiments, the protein under test (0.2 mg/ml) was 
dissolved either in 50 mM phosphate buffer pH 7.0, containing 0.1 M sodium fluoride, 
or in 15 mM glycine buffer, pH 2.5, containing 0.15 M sodium chloride. The 
temperature was increased from 20° to 90°C at a rate of 2°C/min. The CD signal at 
215 nm was acquired at 1 °C intervals.  
Thermal unfolding curves are shown in Fig. 29. The curves show a single transition,  
indicating that a two-state unfolding process occurred for both mnei and oryc at pH 
7.0 and pH 4.0, as expected for proteins of their size (about 10 kDa) [166]. Moreover, 
thermal unfolding was found to be reversible at pH 2.5 when temperature was 
lowered again to 20°C (data not shown), consistent with the previous data (Fig. 24 
and 27).  
 
 
 
Fig.29: Thermal unfolding curves of mnei (blue lines) and oryc (red lines) in 
phosphate buffer at pH 7.0 (dark lines) or in glycine buffer at pH 2.5 (bright
lines). 
To perform a thermal unfolding analysis, the two-state model represented in the 
Methods section was used. 
The parameters obtained from this analysis are shown in Table V.  The values 
indicated that both proteins are less stable at pH 2.5 than at pH 7.0 and that at both 
pH values mnei is more stable than oryc.  
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PROTEIN pH Tm (°C) 
ΔHm 
(kcal/mol) 
ΔG at 20°C 
(kcal/mol) 
Unfolded protein 
at 20°C (%) 
Mnei 7.0 73.7 86.6 7.7 0.0004 
OryC 7.0 94.7 76.0 4.8 0.1 
Mnei 2.5 66.1 79.6 6.6 0.003 
OryC 2.5 73.2 50.1      2.1 5.5 
 
Table V: Thermal unfolding data of mnei and oryc at pH 4.0 and 7.0.  
 
3.4  ThT fluorescence measurements 
To verify whether the loss of signal detected in the CD spectra of mnei were to be 
ascribed to protein aggregation in the presence of fibrilar structures, we performed 
the ThT fluorescence assay.  
As reported above, ThT has a selective response to amyloid fibrillar structures, so 
this assay is indicative of the presence of amyloid fibrils. Upon binding to amyloid 
fibrils, ThT undergoes characteristic spectral changes [178] consisting in an increase 
and in a shift  of the major maximum of fluorescence emission from 438 nm to 482 
nm  [179]. Spectra were recorded in the wavelength interval 455-600 nm upon 
excitation at 442 nm. Proteins were incubated at 100 μM concentration at 86°C in 15 
mM glycine buffer, pH 2.5, containing 0.15 M sodium cloride. ThT fluorescence 
emission spectra were acquired every 30 min by mixing 7 μL of the protein solution to 
800 μL of the ThT solution (20 μM ThT in 25 mM phosphate buffer, pH 7.5). ThT 
fluorescence emission spectra were acquired immediately after protein addition, in 
order to avoid  perturbation of the fibrillar material due to the transition from acidic pH 
to pH 7.0.   
The spectra of ThT in the presence of mnei showed the typical shift and the increase 
in ThT fluorescence emission associated to the presence of fibrillar structures,  
whereas for oryc these characteristic behaviour was not detected (data not shown). 
In Fig. 30, the kinetics of the variations of fluorescence emission intensity at 482 nm 
is shown. When mnei was analysed, we found that the increase in ThT fluorescence 
emission started after about 2 hours of incubation (Fig. 30, green squares).  
 
 
Fig. 30: Kinetics of ThT fluorescence emission at 482 nm during incubation at pH 
2.5 of  mnei (green squares) or oryc (red dots). 
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By contrast,  ThT fluorescence emission intensity relative to oryc was found to 
remain constant during the period of analysis (Fig. 30, red circles). This indicated that 
fibrillogenic structures, generated by mnei and able to bind ThT, appeared during the 
aggregation process.  
 
3.5  Gel-filtration analyses 
Gel-filtration chromatography was performed in order to analyse species size formed 
during the incubation of monellin and oryc at pH 2.5. 
Mnei and oryc proteins were incubated (100 μM) at 86°C in 15 mM glycine buffer, pH 
2.5, containing 0.15 M sodium cloride and then analysed by gel-filtration 
chromatography after 0, 3 and 6 hours of incubation. The results are shown in Fig. 
31. Non incubated mnei (t0) was found to be eluted at an elution volume consistent 
with a monomeric species (Fig. 31A). The same pattern was obtained after 3 and 6 h 
of incubation. Nevertheless, the peak area corresponding to this monomeric species 
appeared to be decreased after 3 and 6 h of incubation by about 50% and 80%, 
respectively. This suggested that during the incubation the soluble monomeric 
protein was sequestered to form insoluble higher molecular weight species, that were 
not eluted from the column. 
 
 
A B
C D
Fig. 31: Gel-filtration analyses of mnei and oryc during incubation at 86°C (A and 
C, respectively) and 50°C (B and D, respectively). Black lines lines refer to the 
patterns of non incubated proteins (time 0), grey lines and orange lines refer to 
the patterns obtained after 3 h and 6 h, respectively. Asterisks correspond to the 
elution volume of molecular mass standards (from left to right: albumin, 67 kDa; 
ovalbumin, 49,1 kDa; chymotripsinogen, 20 kDa; RNasi A, 13,7 kDa).  
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Also oryc protein at time 0 was eluted with an elution volume consistent with a 
monomeric form (Fig. 31C). Nevertheless, during incubation protein precipitation 
occurred and no protein was eluted by the column after 6 h incubation. In order to 
avoid the precipitation of oryc, the incubation temperature was lowered to 50°C.  In 
these conditions, a gel-filtration analysis after 3 and 6 h incubation (Fig. 31D) showed 
a new species eluted earlier than the monomeric species. For this species, which 
represents about 40% of the total protein after 3 h, and about 60% after 6 h, a 
molecular mass of about 36 kDa  was calculated. 
We hypothesised that the 36 kDa species is a trimeric species and that the formation 
of this stable oligomer impairs the protein aggregation in amyloid like structures. This 
hypothesis is in line with the results obtained with the ThT assay. Moreover, the gain 
of structure of oryc at high temperature and low pH (see CD analyses) confirms the 
hypothesis on the formation of new occurring species.  
Finally, when mnei was incubated at 50°C, no aggregation occurred, as the amount 
of the monomeric species determined by gel-filtration (Fig. 31C) was found to be 
unchanged after 3 and 6 h incubation with respect to time 0. 
 
In line with the results reported above, preliminary results obtained by AFM analyses 
indicated that mnei is able to generate typical fibrils (data not shown). 
 
From our analyses, the following aggregation pathway can be described for mnei and 
oryc. Both proteins are stable and undergo a two-state unfolding process upon 
thermal denaturation in acidic conditions. Furthermore, both proteins undergo a 
reversible and temperature-induced transition from β−sheet to a random coil 
structure.  
Prolonged incubation of mnei under acidic pH triggers the transition to a β−sheet 
structure, followed by aggregation. Mnei aggregates show the typical amyloid 
structure, as described by preliminary AFM analyses, and are able to bind ThT.  
By contrast, aggregates of oryc generated under the same conditions, do not present 
any fibrillar structure. Oligomeric species (trimers) were isolated by gel-filtration 
chromatography. We proposed that these species impair or slow down the amyloid 
fibril formation of oryc. 
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4. Catalytic amyloid fibrils 
 
4.1  Designing catalytic amyloid fibrils 
Once established the ability of the fibrillogenic polypeptide of ApoA-I to generate 
ordinate polymeric structures, we planned to exploit the possibility of preparing 
amyloid fibrils catalytically active, by conjugating the fibrillogenic polypeptide to a 
suitable enzyme.  
Construction of catalytic amyloid fibrils is based on two assumptions. First, the 
protein chosen as the building block of the amyloid fibrils must be able to aggregate, 
retaining the typical β−cross amyloid structure, even in the presence of a coupled 
catalytic moiety. Second, the catalytic activity must be retained even upon protein 
aggregation in the polymeric amyloid structure. 
To prepare catalytic amyloid fibrils by protein engineering, we chose the [1-93]ApoA-I 
polypeptide as the fibrillogenic moiety and the glutathione S-transferase (GST) 
enzyme as the catalytic moiety, by fusing them in a chimeric protein, indicated as 
GST-[1–93]ApoA-I.  
GST was chosen as the catalytic partner, as this model enzyme is well characterized 
both structurally and functionally [182]. Moreover, this enzyme is widely used for 
biotechnological applications, such as bioremediation and removal of toxic 
compounds [183]. Nevertheless, technical problems to accomplish this project were 
to be faced, such as the propensity of GST to generate amorphous aggregates, to 
irreversibly denaturate upon stressing conditions, and to form covalent multimers in 
oxidizing conditions. 
  
4.2  Expression and isolation of the fusion protein GST-[1–93]ApoA-I  
The chimeric DNA fusion construct, carrying the GST coding sequence positioned 
upstream to the [1–93]ApoA-I coding sequence, was obtained as previously 
described. The fusion protein was expressed in E. coli BL21(DE3) cells and purified 
from bacterial extracts using a GSTrap affinity column. SDS-PAGE and Western 
blotting analyses of the samples obtained by the purification procedure are shown in 
the paragraph where the isolation of [1–93]ApoA-I is described  (Fig. 9 A and B, 
lanes 1 to 4).  
To further purify the fusion protein, anionic exchange chromatography was 
performed. This procedures was preferred to a reverse-phase chromatography, as 
the latter was found to irreversibly denature the GST enzyme. The fusion protein was 
dialyzed against  buffer A at pH 8 and loaded on a Resource Q column equilibrated 
in buffer A, following the procedure described in the Methods section.  
The chromatographic profile is shown in Fig. 32. SDS-PAGE and Western blotting 
analyses  of all the fractions eluted by the column (data not shown) indicated that 
fractions corresponding to peak C contain the expected fusion protein. These 
fractions were pooled and analysed. In Fig. 33 A,  the results of the SDS-PAGE 
analysis indicated the presence of a single species with the expected molecular 
mass (36 kDa) of the fusion  protein. Western blot analyses (Fig. 33 B and C), 
performed using anti-ApoA-I antibodies (B) or anti-GST-antibodies (C), indicated that 
the protein was  immunopositive to both antibodies. This confirmed that the expected 
fusion protein had been isolated as a pure product.  
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Fig. 32. Ion exchange chromatography profile of the recombinant fusion protein
GST-[1–93]ApoA-I. The elution gradient (orange line) and absorbance values at
278 nm (black line) are shown. The arrow indicates the peak corresponding to
the fusion protein.
b
c
a
 
 
Using this procedure we were able to purify to homogeneity the fusion GST-[1–
93]ApoA-I protein with a recovery of more than 5 mg/L of bacterial culture.  
Fig. 33 (A) SDS–PAGE analysis of the recombinant fusion protein GST-[1–
93]ApoA-I isolated by ion exchange chromatography. Western blot analyses 
were performed using anti-ApoA-I-antibodies (B) or anti-GST-antibodies (C). 
Samples were analysed before (lane 1) and after (lane 2) ion exchange
chromatography. The arrows indicate the GST-[1-93]ApoA-I fusion protein. 
In parallel experiments, we expressed and isolated the GST protein as a recombinant 
ctive enzyme to be used as a control in our experiments.  a
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4.3  Characterisation of GST-[1–93]ApoA-I  
 
4.3.1  GST-[1–93]ApoA-I catalitic activity 
To test the catalytic activity of the GST moiety of the fusion protein we performed 
enzymatic assays in the presence of reduced glutathione (GSH) and of the 
chromogenic compound 1-chloro-2,4-dinitrobenzene (CDNB), commonly used to test 
GST activity [160]. During the reaction, a dinitrophenyl thioether is produced, that can 
be measured by the increase of absorbance at 340 nm using a UV/vis 
spectrophotometer: 
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As in this reaction a small fraction of glutathione and CDNB react spontaneously, i.e. 
by a non catalyzed reaction, the corresponding fraction of non-catalytically generated 
product  had to be subtracted (baseline reaction) from the total amount of product 
obtained. 
A typical GST activity assay is shown in Fig. 34, where the activity of the GST 
enzyme (black line) was measured recording the absorbance variation at 340 nm 
during the reaction. The assays were performed in 0.1 M potassium phosphate buffer 
at  pH 6.5, following the  protocol described in the Methods section. The ΔA value 
obtained in 1 min with 1μg of enzyme was calculated to be  ΔAmin-1μg-1 = 0.17. The 
same test, but in the absence of  the enzyme was performed to determine the 
baseline reaction (ΔA min-1 = 0.0033). When the fusion protein was tested under the 
same conditions (Fig. 34 orange line), the GST moiety was found to almost fully 
retain its enzymatic activity (ΔA min-1 μg-1 = 0.16).  
These results indicated that the GST enzyme fused to the fibrillogenic peptide is fully 
active. 
 
4.3.2   Far-UV CD analyses of the fusion protein 
 A correct, native fold of the GST moiety in the chimeric protein is essential to 
preserve its catalytic activity. Nevertheless, the presence of the fibrillogenic moiety 
might alter the correct folding of the GST, therefore impairing its activity. This could 
be particularly true in the case of [1–93]ApoA-I, known to be a natively unfolded 
polypeptide.  
In order to assess the secondary structure content of the GST-[1–93]ApoA-I fusion 
protein, we performed far-UV CD analyses of GST-[1–93]ApoA-I. We used as a 
control a recombinant form, pure and fully active, of GST enzyme. In Fig. 35 CD 
spectrum of GST (5 μM) at 25°C in buffer A at pH 8 is shown. GST was found to 
have typical characteristics of an α/β protein, with a predominance of the α-helical  
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Fig. 34. Analysis of the enzymatic activity of the fusion protein. The chimeric 
protein (orange line) was tested in the presence of glutathione and CDNB. GST 
was tested under the same conditions as a control (black line). A non enzymatic 
reaction was also performed (blue line).  
signal (Fig. 35, black line), in agreement with the data riported in the literature [182]. 
The spectrum of GST-[1–93]ApoA-I performed under the same conditions, was found 
to be almost superimposable to that of GST, having only a slightly higher content of 
random coil structure, to be probably ascribed to the presence of the natively 
unfolded [1–93]ApoA-I moiety (Fig. 35, orange line).  
 
 
 
Fig. 35. Far-UV CD spectra of the fusion protein (red line) and of GST (blue line) 
at pH 8. 
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Notably, the spectra deconvolution obtained with the CDPro program (Selcon3, 
CDSSTR, and Continll methods, data not shown) indicated that the  presence of the 
[1–93]ApoA-I polypeptide at the C-terminus of the chimeric protein did not 
significantly affect the secondary structure of GST.  
These results are consistent with the results obtained on the GST-[1–93]ApoA-I 
catalitic activity and indicate that the fusion protein retains both the native fold and 
the catalytic activity of the GST protein. 
 
4.4  Analyses of  the fibrillogenic potential of the fusion protein GST-[1–
93]ApoA-I 
 
4.4.1 In silico characterization of the GST-[1–93]ApoA-I fusion protein 
An in silico analysis of the fusion protein was performed in order to predict its 
aggregation potential. First, the instability index [167] of the fusion protein, as well as 
that of GST as a control, were analysed and found to be 39.37 and 36.62, 
respectively. These values indicated that both proteins are stable. On the contrary, 
the instability index calculated for [1–93]ApoA-I (46.67) indicated that this protein is 
unstable.  
Using the Tango algorithm [62] (Fig. 36) 2 main regions of the fusion protein were 
predicted to have aggregation propensity at pH 7.0 (red line): a region associated to 
high aggregation propensity, localised at residues 236-249 of the [1–93]ApoA-I 
moiety (orange bar), and a region with a minor propensity to aggregation, localised in 
the GST moiety (residues 161-165). For both regions, the propensity to aggregation 
was found to be significantly increased when tested at pH 4.0 (blue line).  
Thus, the region with the highest propensity to aggregation is localised in the [1–
93]ApoA-I moiety, as expected. This analysis also suggested that at both pH values 
the overall aggregation propensity of the fusion protein is significantly higher than 
that of GST, clearly due to the presence of the [1–93]ApoA-I moiety (Fig. 36). The 
overall aggregation values (AGG) calculated for both proteins at pH 7.0 and 4.0 are 
reported in Fig. 36. 
 
 
Fig 36: Tango analysis of the aggregation propensity of GST-[1–93]ApoA-I at 
pH 4 (bue line) and pH 7 (red line). The overall agregation propensity (AGG)
value for GST and GST-[1–93]ApoA-I at pH 4 and 7 are also reported. The 
orange bar corresponds to the sequence of [1–93]ApoA-I
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4.4.2  Spectroscopic analyses of  GST-[1–93]ApoA-I fusion protein 
 In order to analyse the ability of the fusion protein to undergo conformational 
transitions and to form amyloid fibrils, we performed spectroscopic analyses using 
specific dyes such as ANS, ThT and CR. Recombinant GST was used as a control. 
The aim of these analyses was to verify whether the chimeric protein retained the 
spectroscopic characteristics of a fibrillogenic protein. 
 
4.4.3  ANS binding  
ANS, a very common fluorescent probe for protein studies, has been used to 
monitor protein conformational changes, as it binds to exposed hydrophobic regions 
of proteins. As a consequence, when a conformational transition occurs, the 
fluorescence intensity of ANS increases and the emission spectrum maximum shifts 
from 520 nm to 470 nm [17]. 
Binding of ANS to the fusion protein or to GST, induced by pH acidification, is 
shown in Fig. 37 A and B, respectively. ANS emission fuorescence spectra were 
recorded in the range of 400–600 nm at the excitation wavelength of 380 nm.  
The results indicated that: (i) for both proteins spectra at pH 8.0 were found to be 
almost identical to the spectrum of ANS dye; (ii) when the pH value was lowered to 
6.4, for both proteins a blue shift and a significant increase in the maximum of 
fluorescence emission were detected; (iii) when the pH value was returned to 8.0, for 
both proteins the spectral changes were reverted.  
 
 
 
Fig. 37: pH-induced binding of ANS to fusion protein (A) or GST (B). ANS 
spectra at pH 8.0 are shown in blue whereas spectra at pH 6.4 are shown in 
orange. In green are shown the spectra registered upon returning to pH 8.0. 
Spectra of the dye are shown (C)  at pH 8.0 (green) and 6.4 (orange). 
A B
C
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In conclusion, according with CD analyses, both proteins at pH 8.0 are correctly 
folded; no hydrophobic regions are exposed to the solvent. Upon acidification, a pH 
induced conformational transition occurs for both proteins, which expose to the 
solvent hydrophobic regions previously buried in the protein core. This transition is 
frequently found in the early step of the fibrillogenic pathway of proteins [175] and it 
has been related to a molten globule state. However, no  spectral differences were 
detected between the GST and fusion protein. In the literature, fluorescence 
analyses of the early unfolding process of GST have been reported that confirm our 
results [184]. 
 
4.4.4  Thioflavin T assay 
As the pH induced conformational transition is known to be an early event occurring 
in the fibrillogenic pathway of some amyloidogenic protein [38], we searched for the 
presence of amyloid structure generated during long time protein incubation in buffer 
A at pH 6, using the ThT dye binding assay. As previously reported,  Thioflavin T has 
been widely used in the in vitro fluorometric analyses to detect amyloid fibrils, as it 
associates rapidly with the aggregated fibrils. Upon binding, the excitation and 
emission maxima were shifted from 385 nm and 445 nm, respectively, to 450 nm and 
482 nm, respectively. 
Proteins (10 μM) were incubated at 25°C in buffer A in the presence of ThT 15 μM. 
The increase of the ThT emission fluorescence at 482 nm (excitation 450 nm) was 
recorded using a spectrofluorimeter.   
In Fig. 38A the results of our experiments are reported. For the fusion protein (blue 
circles), a time dependent increase of emission fluorescence was detected. The 
obtained curve is typical for amyloid polymerisation kinetics, with a short lag phase 
(about 3 h). These results indicated that during GST-[1–93]ApoA-I incubation, 
amyloid-like structures were generated, able to bind the ThT dye. 
By contrast, ThT fluorescence emission did not change significantly during the 
incubation of GST under the same conditions (red squares Fig 38A), suggesting that 
no amyloid-like structures occurred during incubation. 
When the aggregation curve of GST-[1–93]ApoA-I was compared to the aggregation 
curve of the fibrillogenic polypeptide [1–93]ApoA-I (see Fig. 15), the conclusion could 
be drawn that the presence of GST increased the fibrillogenic potential of [1–
93]ApoA-I polypeptide. In fact, it is well known that the protein context plays an 
important role in determining the stability and solubility of fibrillogenic polypeptides 
and may modulate the aggregation properties of amyloidogenic fragments [185].  
Following these experiments, SDS-PAGE and Western blot analyses under reducing 
conditions were performed on GST-[1–93]ApoA-I samples. Besides the presence of 
monomeric  GST[1–93]ApoA-I species, the presence of species with high molecular 
weight (Fig 38B) was detected and found to be immunopositive to anti-ApoA-I 
antibodies (Fig.38C). The fact that these species were detected under denaturing 
and reducing conditions, suggested that they are very stable, although non covalently 
linked. As a consequence, we might exclude that aggregation by disulphide bridges 
occurs as sometimes reported in the literature for GST [186]. 
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Fig. 38:  (A) The increase of ThT emission fluorescence at 482 nm during the 
incubation at 25°C of the fusion protein (blue circles) or GST protein (red 
squares). (B) SDS-PAGEand (C) Western blot analyses of the fusion protein 
tested at the end of the experiment reported in (A). Lane 0, molecular weight 
standards,  Lane 1, the non incubated protein; lane 2, the incubated protein. 
0         1        2                             1          2 
        A 
B   C 
4.4.5  Congo Red analyses 
To further characterise the putative amyloid-like structure of GST-[1–93]ApoA-I, we 
also performed Congo red assays. CR is believed to specifically interact in some 
unknown way with the crossed-β-sheet structure common to amyloid structures. As 
previously described, the Congo red assay is a differential spectroscopic assay, in 
which the Congo Red bound fibrils is measured by means of a typical spectral red 
shift of the adsorption maximum, from 490 nm to 540 nm in the spectrum of the 
Congo red-protein complex. GST-[1–93]ApoA-I, or GST as a control, were incubated 
in the same conditions described for ThT assays. After about 60 h of incubation, CR 
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assays were performed by diluting each protein to 100 μg/ml followed by the addition 
of Congo Red dye (20 μM) [176].  
The results are shown in Fig. 39. By subtracting both the spectrum of GST-[1–
93]ApoA-I alone (green line, Fig. 39 A), indicative of the light scattering phenomen, 
and that of Congo red alone (blue line, Fig. 39 A) from the spectrum of GST-[1–93] 
ApoA-I in the presence of Congo Red (orange line, Fig. 39 A), a differential spectrum 
was obtained (Fig. 39 C, red line). This spectrum showed the typical maximum red 
shift indicative of Congo Red binding to fibrillar structure. This suggested the 
presence of polymeric amyloid β-cross structures, in line with the data obtained with 
ThT. 
When the same experiments were performed with GST (Fig. 39B), no red shift was 
detected, indicating the absence of amyloid structures, in line with the results, 
obtained with ThT. 
 
 
 
    A         B   
Fig. 39: Congo Red spectra in the presence of the fusion protein (A) or GST (B). 
The spectra of the proteins in the presence of Congo Red are in orange; the 
spectra obtained with proteins alone are in green; those of Congo Red are in 
blue. (C) The differential spectra of the complexes fusion protein-Congo Red (red 
line) or GST-Congo Red (gray line), obtained by subtracting the green and blue
spectra from the corresponding orange spectrum.  
   C    
Taken together, the spectroscopic data collected using different methodologies (CD, 
ANS, ThT, CR) strongly suggested that: (i) for both fusion protein and GST, a molten 
globule state is induced by lowering the pH; (ii) the chimeric protein GST-[1–
93]ApoA-I is able to evolve towards a fibrillogenic, amyloid-like structure; (iii) GST 
being unable to polymerize, generates amorphous aggregates. 
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4.4.6  Morphological analysis of fusion protein aggregates 
The fusion protein GST-[1-93]ApoA-I (0.2 mg/ml) was incubated under conditions 
that promote fibrillogenesis, i.e. 1 week at 25°C, at pH 6.4. Following incubation, the 
insoluble protein fraction, recoved by centrifugation, was analysed by AFM by the 
group of Prof. A. Gliozzi, University of Genova on mica surfaces.  
Typical fbrillar structures were detected. In Fig. 40, protofilaments generated by the 
fusion protein self-assembly, are shown. The presence of heterogeneous aggregated 
material was also described (not shown). 
 
 
 
Fig. 40: AFM images fibrils generated by the fusion protein. 
4.5   Analysis  of  the catalytic activity of GST-[1–93]ApoA-I fibrils 
Once verified that the fusion protein in its soluble state retained the GST catalytic 
activity, and that it was able to form amyloid-like structures, we tested the catalytic 
activity of these fibrils. 
Following the procedure to induce fibril formation (i.e. incubation for at least 1 we3ek 
at pH 6.4), the protein was dried and resuspended in buffer A at pH 6.5. Soluble and 
insoluble fractions were separated by centrifugation and tested by the CDNB assay.  
The results are reported in Fig. 41A, where the increase of absorbance at 340 nm 
was determined after 45 min of reaction. The insoluble material, generated during the 
incubation at pH 6.4, was found to be enzymatically active, whereas low levels of 
activity were found to be associated to the corresponding soluble fraction.  No activity 
was instead found to be associated to the aggregated material generated at pH 4.0, 
which suggested that in acidic conditions amorphous, inactive aggregates were 
prevalently produced. 
The same samples were also analysed by SDS-PAGE under reducing conditions. 
This analysis showed that high molecular weight species were present in the protein 
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incubated at pH 6.4  (Fig. 41B). These specie were not detectable in the non 
incubated protein, or in the protein incubated at pH 4.0. 
As the SDS-PAGE analysis was performed under reducing conditions, we might 
exclude  that the insoluble material, enzymatically active, was generated by oxidative 
reactions, such as S-S bridges formation. In fact, it is known that GST under non 
reducing conditions generates covalently linked aggregates without loss of enzymatic 
activity. 
 
 
 
Fig. 41:  (A) CDNB assay of the chimeric protein aggregates generated after 7
days incubation at pH 6.4 (blue bars) or pH 4.0 (red bars). The soluble and 
insoluble protein fractions were tested. (B) SDS-PAGE analysis in reducing 
conditions  of the chimeric protein aggregates. In this case, the total protein was 
analysed without separating soluble from insoluble fraction. Lane 1, GST-[1–
93]ApoA-I; lane 2, molecular weight standards; Lane 3, aggregates of GST-[1–
93]ApoA-I generated at pH 4.0; Lane 4, aggregates generated at pH 6.4 (lane 
4). 
A 
              1      2      3       4
B 
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These results are in line with the data collected by ThT.  
The hypothesis can be raised that, whereas at pH 4.0 most of the protein precipitates 
in amorphous aggregates with loss of catalytic activity, at pH 6.4, typical amyloid 
fibrils are generated. These ordered structures may thus be viewed as a new enzyme 
linked polymeric support. Thus, a new catalytic matrix was produced starting from 
brillogenic polypeptide.  
re then 
ed on filters, as well as that of the protein fraction washed out from 
 was expressed as the increase of 
he results of these experiments are shown in Fig. 42. 
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4.6  Trapping the catalytic amyloid fibrils onto a solid support 
To immobilise the catalytic amyloid fibrils on a solid support, such as filters,  PVDF  
membranes were chosen with a cut-off of 0.02 or 0.2 μm. Filters were not activated, 
as usually recommended by the manufacturers, to avoid protein binding and allowing 
filters to trap exclusively high molecular weight species. A suspension of fibrillar 
species (1 ml) was filtered through the two types of membranes; the filters we
washed with 5 ml of buffer in order to remove low molecular weight species.  
CDNB assays were then performed to test the enzymatic activity of the fibrillar 
species immobilis
the filters.  
Then, the enzymatic activity associated to the fibrils immobilised onto 0.02 μm or 0.2 
μm filters was tested in parallel experiments. To perform these assays, each filter, 
positioned within its plastic holder, was connected to a peristaltic pump. The reaction 
mixture, containing the substrates of the GST enzyme, was let to pass continuously 
through  the filter for 10 min. The enzymatic activity
the absorbance recorded after 10 min of reaction. 
T
 
 
Fig. 42: Catalytic fibrils were loaded on filters with cut-off of 0.02 or 0.2 μm and 
then washed with buffer. After 10 min of CDNB reaction, the absorbance 
variations were determined for both samples, as well as for the washed out 
material.  
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As shown in the Figure, fibrils immobilised on filters with cut-off 0.02 μm were found 
to be enzymatically active, i.e. able to generate the expected reaction product. No 
activity was found instead to be associated to fibrils loaded on filters with 0.2 μm cut-
off. 
This indicated that the size of the fusion protein fibrils were too small to be trapped 
on filters with cut-off 0.2 μm, but sufficiently large to be trapped by 0.02 μm cut-off 
filters.  
Some enzymatic activity was also detected in the protein fraction washed out by the 
filters, indicating that some low molecular weight species, possibly small oligomers, 
were also present in the fibrillar material.  
These results indicated that fibrils generated by the chimeric protein are costituited 
by self-assembled high molecular weight polymers, endowed with catalytic activity.  
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DISCUSSION 
 
1. The recombinant fibrillogenic polypeptide [1-93]ApoA-I  
Amyloidogenic proteins and peptides have high propensity to aggregate in fibrillar 
structures [49]. The presence of specific mutations, and/or environmental conditions, 
that tend to destabilize the native conformation of a fibrillogenic proteins, represents 
the principal cause that may kinetically favour aggregate nucleation. In amyloid 
diseases associated to apolipoprotein A-I (ApoA-I), the major component of high 
density lipoproteins (HDL), the pathogenesis is associated to the presence of 
mutated versions of the 243-residue native protein [84]. Fibrils extracted from 
amyloid deposits were found to be mainly constituted by N-terminal fragments of 
ApoA-I, about 90-100 residue long [101]. In particular, the polypeptide 1-93 was 
found to be the main constituent of cardiac fibrils extracted from patients affected by 
amyloidosis, harbouring the mutation L174S in the full length protein.  
The 93-residue ApoA-I polypeptide, extracted from ex-vivo fibrils, is a “natively 
unfolded protein” at neutral pH, but at pH 4 it undergoes a complex fibrillogenic 
pathway [102]. The difficulty to obtain the natural polypeptide from ex-vivo sources in 
sufficient amount made so far impossible further structural and functional studies. 
Despite the instability of the fibrillogenic polypeptide, we succeeded in the production 
and isolation to homogeneity of a stable recombinant form of the 93-residue 
fibrillogenic domain of ApoA-I, denoted as [1-93]ApoA-I [174].  
In this work we cloned, expressed and purified the [1-93]ApoA-I polypeptide using an 
effective and reliable expression system to produce the recombinant form of the 
amyloidogenic polypeptide. 
The recombinant 1-93 ApoA-I polypeptide was expressed in bacterial cells following 
an experimental strategy aimed at reducing the intracellular degradation during its 
production. Briefly, the polypeptide was expressed as a chimeric product, obtained 
by fusing the polypeptide to a stable bacterial protein. The polypeptide was then 
released by site-directed proteolysis and isolated as a stable, pure protein.  
The final product was analyzed to investigate its conformational properties and 
fibrillogenic potential, using a multidisciplinary approach. 
Conformational dynamics of the recombinant [1-93]ApoA-I was inspected by CD and 
fluorescence analyses. A conformational switch from a random coil to a molten 
globule/helical conformer, able to bind ANS,  was clearly detected by lowering the pH 
from 7 to 4 [174], as it has been described for the natural polypeptide [102]. The 
transition was found to be fully reversible when the pH is returned to 7.  
We proposed that the helical conformer is a key intermediate in the fibril formation 
pathway and that its generation represents an early and reversible event in the 
fibrillogenic pathway.  
The helical/molten globule intermediate displayed a strong propensity to oligomerize. 
During a prolonged incubation at pH 4.0 it was found to switch towards a 
predominant β-sheet based structure that evolves to an insoluble polymeric structure.  
The experimental data obtained from conformational analyses are in line with the in 
silico analysis of the aggregation propensity of [1-93]ApoA-I, performed with the most 
common predicting  algorithm available (Tango algorithm). The polypeptide was 
predicted to have a high and pH-dependent aggregation propensity. 
Further characterisation of the aggregated material was performed using amyloid 
specific dyes, as thioflavin T (ThT) and Congo Red (CR). These analyses indicated 
that the aggregated material is organized in regular and ordered polymeric amyloid 
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structures. In these assays, the acidification emerged as a condition able to increase 
the rate of amyloid formation, as found for the most common amyloidogenic proteins 
[38]. 
Gel-filtration analyses of [1-93]ApoA-I showed that the polypeptide is a dimer under 
physiological conditions. Incubation of the polypeptide under acidic conditions, 
followed by the gel-filtration analyses, showed the disappearance of the dimeric 
species, presumably sequestered in insoluble oligomers. Interestingly, the existence 
of dimeric species had been also suggested by previous experiments, performed by 
Prof. P. Pucci of the University of Naples, using limited proteolysis coupled with mass 
spectrometry.  
The data collected in the laboratory of Prof. A. Gliozzi of the University of Genova, 
which collaborates with our group as an expert of microscopy techniques, showed 
that the recombinant polypeptide, analysed by Atomic Force Microscopy, is able to 
generate fibrils in a time scale comparable to that of its natural counterpart. Upon 
incubation of the polypeptide in acidic conditions, narrow protofilaments and well-
defined fibrils were detected together with globular aggregates.  
From our data, a complex and multistep intriguing aggregation pathway emerges for 
[1–93]ApoA-I. Major conformational rearrangements are involved and different  
intermediate species with own structural characteristics are generated during the 
aggregation process, in complete agreement with the data obtained for the natural 
peptide  [102]. Our analyses strongly suggest that a delicate balance between 
natively stabilizing interactions and pathological propensity to self-aggregation exists, 
stressing the importance of environmental conditions in the maintenance of protein 
conformation. 
 
2. Towards the understanding of the molecular bases of [1-
93]ApoA-I aggregation 
The role of mutations in increasing the propensity of proteins to aggregate is a crucial 
aspect in the ApoA-I amyloidoses, where the disease is invariably associated to the 
presence of specific mutations in ApoA-I gene.  
All the patients analysed so far were found to be heterozygous for the mutated 
protein. Nevertheless, the observation that, when an internal mutation occurs, i.e. a 
mutation located in the N-terminal domain of ApoA-I, almost only the polypeptide 
carrying the mutation was detected in fibrils. This suggests a role of amyloidogenic 
mutations in modulate the aggregation propensity of [1-93]ApoA-I polypeptides.  
As discussed above, 8 mutations in the N-terminal domain of ApoA-I have been 
demonstrated so far to be associated to amyloid pathologies.  
The availability of a suitable protocol to express [1-93]ApoA-I encouraged the 
production of its amyloidogenic variants. This will open the way to a detailed 
comparative study on the conformational dynamics and fibrillogenic potential of the 
mutated forms versus the wild type polypeptide, aimed at the comprehension of the 
molecular mechanism by which mutations in ApoA-I promote amyloid deposition. 
Following the protocol set up for [1-93]ApoA-I, we were able to express and isolate to 
homogeneity the 8 mutant versions of [1-93]ApoA-I polypeptide, thus generating the 
complete panel of variants of the 93-residue ApoA-I fibrillogenic polypeptides 
(Guglielmi et al., manuscript in preparation).  
Six of them harbour a single residue substitution (mutants G26R, T50R, L60R, L64P, 
L75P and L90P), whereas two mutants harbour a deletion at sequence 70-72 and 
60-71, respectively (in the latter case the deleted sequence is replaced by VT) [84]. 
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Experiments aimed at the characterization of the conformational state and structural 
dynamics of the 8 amyloidogenic variants of [1–93]ApoA-I are in progress. 
Preliminary data, obtained in collaboration with Prof. V. Bellotti of University of Pavia, 
indicated that almost all mutants display an increased aggregation propensity with 
respect to wild type [1-93]ApoA-I. 
The availability of recombinant forms of wild type [1-93]ApoA-I and its mutated 
versions represents a powerful in vitro system to perform a systematic study on the 
effects of each mutation on the fibrillogenic potential of these polypeptides. Further 
investigation of [1–93]ApoA-I polypeptides, using independent experimental 
approaches, such as CD, fluorescence and microscopy, will integrate our preliminary  
results, with the aim to define a suitable algorithm able to correlate structural 
determinants to functional features.    
In the next future, our molecular system will be used to analyse the molecular bases 
of ApoA-I amyloidosis. In this regard, the understanding of the mechanism of 
amyloidosis represents an important step towards the designing of therapeutic 
approaches aimed at the treatment or prevention of amyloid disease 
 
 
3. Plant cystatins as model proteins to study the fibrillogenic 
process
Plant cystatins are protease inhibitors that represent an interesting model system to 
shed light on cystatins aggregation behavior. These proteins were found to be able to 
form amyloid fibrils under specific conditions [124]. Plant cystatins share structural 
features (the cystatin motif) with human cystatins, which are involved in human 
severe amylopathies. Among them, human cystatin C is responsible the hereditary 
cystatin C amyloid angiopathy, named HCCAA [115], whereas human cystatin B is 
associated to Unverricht- Lundborg disease [117]. 
In the period June-September 2007, I worked at the Medical Research Council 
(MRC), London, National Institute for Medical Research, in the laboratory of Dr. A. 
Pastore. My research project concerned studies on the conformational and 
aggregation properties of two plant cystatin: mnei,  a recombinant, sweet tasting 
monellin, and oryzacystatin I (oryc), a cystatin from Oryza sativa.  
When tested by thermal unfolding analyses, both proteins were found to be very 
stable even at acidic pH. As inferred by conformational analyses performed by CD, 
we found that under acidic conditions these proteins undergo a β−sheet to random 
coil transition, induced by increasing the temperature. Longer exposure of mnei in 
acidic conditions causes the appearance of a β−sheet signal, that is lost upon 
prolonged incubation due to protein aggregation and precipitation. 
Although both proteins were found to aggregate, the aggregated material generated 
by mnei was able to bind amyloid specific dyes, such as thioflavin T, whereas  oryc 
aggregates did not assume amyloid-like structure. Moreover, gel-filtration analyses of 
mnei, after incubation at high temperature, showed the disappearance of the 
monomeric species, reasonably sequestered in protein multimers. 
Interestingly, the time scale of the appearance of mnei β-cross structure, inferred 
from ThT assays, is compatible with the time scale of the conformational transition 
and protein aggregation inspected by CD analyses.  
On the contrary, oryc was found to be able to generate stable trimers, as indicated by 
gel-filtration analyses. To explain the absence of amyloid structures in oryc 
aggregates, we hypothesised that these trimers are able to prevent the protein from 
self-aggregation in amyloid structures.  
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Actually, the presence of dimeric or tetrameric forms of human cystatin, in which the 
subunits are linked together by domain swapping, were demontrated by 
crystallographic and gel- filtration analyses [119, 12].  
Hence, the formation of stable oligomers by domain swapping could be a general 
mechanism to prevent amyloid fibrillogenesis.  
 
 
4. A biotechnological application of amyloid self-assembly 
Molecules may undergo self-association forming hierarchical structures. Self-
assembly can be defined as the spontaneous organization of individual components 
into an ordered, well-defined and organized structure. Molecular self-assembly 
(“molecular Lego”), by definition, is the spontaneous organization of molecules under 
thermodynamic equilibrium conditions into structurally well-defined and rather stable 
arrangements through a noncovalent interactions [11]. Molecular self-assembly is 
emerging as a new route to produce novel materials and to complement other 
materials.  
Amyloid fibrils formed by self-association of polypeptide chains are therefore possible 
candidates for the construction of nanostructured materials, using the bottom-up 
strategy, from single molecules to sopramolecular structures. Amyloid fibrils are of 
interest in the field of protein engineering by means of their well-ordered and 
multidimensional structure [187], the possibility to control the assembly conditions, 
and the presence of weak noncovalent interactions rather than covalent bonds. 
We inspected the possibility to generate new catalytic matrices using the amyloid 
fibril as physical supports on which to align enzyme molecules.  
The definition “catalytic fibrils” has emerged very recently, referred to amyloid fibrils 
on which an enzyme is immobilised [145], although catalytically active fibrils were not 
produced so far.  
R.B. Wickner and coworkers, studying Ure2p inactivation upon aggregation, found 
that, when GST was fused to the fibrillogenic domain of Ure2p, a decreased 
enzymatic activity was detected upon fibrils formation. Similar results were obtained 
when the fibrillogenic domain was fused to enzymes such as barnase, carbonic 
anhydrase or green fluorescent protein (GFP) [156]. Finally, T.R. Serio et al. found 
that GFP fused to the C-terminus of yeast Sup35 is able to self-associate in fibrillar 
structures harbouring green fluorescence [157]. 
 We planned to generate new catalytic fibrils, whose monomeric unit is a fusion 
protein, generated by linking  [1-93]ApoA-I  to the GST protein. The former will act as 
the fibrillogenic moiety, the latter as the catalytic moiety.  GST is  a good candidate to 
generate catalytic fibrils, due to its well known use for biotechnological applications, 
such as biotransformations and detoxification processes.  
The fusion protein was expressed and isolated as a homogeneous product; when its 
catalytic activity was analysed, it was found to fully retain the enzymatic activity of 
GST enzyme.  
The fibrillogenic potential of the fusion protein was extensively investigated using a 
multidisciplinary approach. Upon incubation in slightly acidic conditions, the fusion 
protein was found to bind ANS, ThT and CR dyes, indicating that a pH-driven 
transition occurs that triggers the process of aggregation in amyloid-like structures.   
Upon prolonged incubation under acidic conditions, the formation of insoluble 
material was observed. AFM analyses indicated the in this heterogeneous material 
typical amyloid protofilaments were present.  
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The fibrillar material was then trapped on suitable filters. When the GST reaction 
mixture was let to pass through the filter, the expected product was generated.  
Taken together, our results showed that a chimeric protein, harbouring an enzymatic 
activity and a fibrillogenic domain, was able: (i) to form amyloid fibrils through 
molecular self-assembly; (ii) to retain the catalytic activity of the enzymatic moiety. 
Hence, amyloid structures may act as self-assembled matrices, providing a polymeric 
support to a catalytically active enzyme.  
Fibrils may represent a new tool to generate immobilized enzymes. As amyloid fibrils 
are thought to be solvent filled nanotubes [180], studies will be performed to 
investigate their potential as active matrices, able to crowd enzyme molecules, thus 
enhancing the product production.  
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A variety of amyloid diseases are associated with ﬁbrillar aggregates from N-terminal fragments of ApoA-I generated through a large-
ly unexplored multi-step process. The understanding of the molecular mechanism is impaired by the lack of suitable amounts of the
ﬁbrillogenic polypeptides that could not be produced by recombinant methods so far. We report the production and the conformational
analysis of recombinant ApoA-I 1–93 fragment. Similarly to the polypeptide isolated ex vivo, a pH switch from 7 to 4 induces a fast and
reversible conformational transition to a helical state and leads to the identiﬁcation of a key intermediate in the ﬁbrillogenesis process.
Limited proteolysis experiments suggested that the C-terminal region is involved in helix formation. The recombinant polypeptide gen-
erates ﬁbrils at pH 4 on a time scale comparable with that of the native fragment. These ﬁndings open the way to studies on structural,
thermodynamic, and kinetic aspects of ApoA-I ﬁbrillogenesis.
 2006 Elsevier Inc. All rights reserved.
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E-mail address: piccoli@unina.it (R. Piccoli).loid diseases [1]. A variety of amyloid diseases are
associated with mutations in apolipoprotein A-I (ApoA-
I), for which the process of ﬁbril formation has not yet
been clariﬁed, and a paucity of information exists in com-
parison to the detailed knowledge surrounding other dis-
ease-associated proteins such as lysozyme, transthyretin,
and b2-microglobulin [1]. Analysis of natural amyloid
ﬁbrils has shown that ﬁbrils consist of ApoA-I N-terminal
fragments, 90–100 residues long. Mutations are sometimes
present within the N-terminal portion of the protein that is
224 S. Di Gaetano et al. / Biochemical and Biophysical Research Communications 351 (2006) 223–228eventually found in ﬁbrils (‘‘internal mutations’’), but can
also occur in positions located outside this region of the
polypeptide sequence (‘‘external mutations’’) [2].
Characterization of the polypeptides puriﬁed from natu-
ral ﬁbrils from patients carrying the ‘‘external mutation’’
Leu174Ser has shown that the 1–93 N-terminal portion
of ApoA-I is intrinsically amyloidogenic in a physiological
environment. By using the natural 1–93 polypeptide, we
have shown that acidic conditions (pH 4) induce ﬁbril for-
mation [3]. We envisage a complex aggregation pathway in
which the polypeptide assumes a random coil structure at
neutral pH, shifts into an unstable helical conformation
at acidic pH, and then aggregates into a b-sheet-based
polymeric structure. The investigation of this complex
pathway has been limited so far by the small amounts of
the natural amyloidogenic polypeptide. Attempts to
express an homologous recombinant form either in pro-
karyotic or eukaryotic cells have failed, probably for the
rapid intracellular digestion of the unstructured product.
We describe here the production of recombinant 1–93
polypeptide and the investigation of its structural dynamics
during ﬁbrillogenesis.
Materials and methods
Expression and isolation of Apo A-I 1–93 polypeptide. The cDNA
encoding fragment 1–93 of ApoA-I ([1–93]ApoA-I) was obtained by PCR
ampliﬁcation using full length ApoA-I cDNA as a template, and oligo-
nucleotides 5 0-CGCGGATCCGATGAACCCCCCCAGAG-30 (forward
primer) and 5 0-CCGGAATTCTTACACCTCCTCCAGATCCTTG-3 0
(reverse primer), where restriction sites are underlined. The ampliﬁed
DNA was cloned in the EcoRI and BamHI sites of pGEX-4T-3 expression
vector (General Electric, CT) downstream to the sequence encoding glu-
tathione S-transferase (GST). Competent Escherichia coli BL21DE3 cells
were transformed and induced to express the recombinant protein by the
addition of 0.1 mM IPTG for 2 h at 37 C, using a BioFlo 3000 benchtop
fermentor (New Brunswick Scientiﬁc, NY).
Isolation of recombinant [1–93]ApoA-I. Lysates were obtained upon
treatment of bacteria with 1% Triton X-100 in PBS (30 min, 4 C) in the
presence of protease inhibitors (Roche, Germany), followed by sonication
(Misonix, Farmingdale, NY). The soluble fraction obtained by centrifu-
gation was fractionated by aﬃnity chromatography on a GSTrap gluta-
thione-agarose column. GST-containing species were eluted with 50 mM
Tris–HCl at pH 8.0, containing 10 mM glutathione following the manu-
facturer’s protocol, but in the absence of DTT to avoid inhibition of
thrombin enzymatic activity. Proteins were then digested with 6 U/mg of
thrombin (Sigma) for 30 h at 4 C in the chromatography elution buﬀer.
Products were separated by HPLC reverse chromatography on a Ultra-
pure C8 column (Beckman Coulter, CA) with a linear gradient of aceto-
nitrile in 5 mM phosphate buﬀer at pH 7.4 and analysed by SDS–PAGE
on 15% acrylamide gels. For Western blot analyses anti-human ApoA-I
polyclonal antibodies (DAKO, Denmark) and a chemiluminescence
detection system (West Pico, Pierce) were used. Pure [1–93]ApoA-I was
dialyzed in water, lyophilized, and stored at 70 C until use. The
lyophilized polypeptide was dissolved in phosphate buﬀer at pH 7.4.
About 1 mg of pure [1–93]ApoA-I was obtained from 1 L of bacterial
culture.
In situ hydrolysis and MALDI-MS analysis. The protein band stained
by Coomassie blue brilliant and corresponding to the expected recombi-
nant protein was excised and in situ digested according to [4] and the
peptide mixture was analysed by MALDI as described [5].
Limited proteolysis. Aliquots of 7 lM [1–93]ApoA-I were digested
separately with trypsin, V8 protease, chymotrypsin, elastase, and subtili-sin. Proteolysis was performed at 25 C in 12 mM sodium phosphate at
pH 7.5, using enzyme-to-substrate ratios ranging between 1:800 and
1:4000 (w/w). Proteolysis in the presence of 20% TFE was performed
under the same conditions using enzyme-to-substrate ratios ranging from
1:100 to 1:2000 (w/w). The extent of proteolysis was monitored by sam-
pling the incubation mixture at diﬀerent time intervals. Proteolytic frag-
ments were fractionated and characterized by mass spectrometry as
described [5].
Gel-ﬁltration assay. Gel-ﬁltration experiments were performed with a
SMART system (Pharmacia Biotech) using a Superdex-75 column
(Pharmacia) equilibrated and eluted in 50 mM phosphate buﬀer at pH 7.5,
containing 150 mM NaCl, in the presence or absence of 20% TFE.
[1–93]ApoA-I (4 lg) was dissolved in an appropriate volume of buﬀer with
or without TFE (20%) to a ﬁnal concentration of 7 lM. Experiments were
performed at room temperature at a ﬂow rate of 75 ll/min. The column
was calibrated under the same conditions (either with or without 20%
TFE) with standard proteins.
CD spectra. Circular dichroism spectra were recorded on a Jasco J-710
spectropolarimeter as previously described [3]. Measurements were per-
formed at 20 C at a protein concentration of 0.3 mg/ml in 3 mM glycine,
3 mM sodium acetate, and 3 mM sodium phosphate at pH 7 (buﬀer A).
Acidiﬁcation and neutralization of the solution were carried out as pre-
viously described [3]. CD data were expressed as mean residue ellipticity
(h).
Fluorescence spectra at the equilibrium. By observing the intrinsic
ﬂuorescence emission of tryptophan in the range 300–550 nm and exci-
tation at 295 nm, we monitored the conformational transition induced by
the pH jump from 7 to 4. Measurements were carried out at 20 C in a 10-
mm cell by using a Perkin-Elmer LS50 spectroﬂuorimeter and the slit
widths set at 5 nm. Protein solution (0.06 mg/ml) was ﬁrst analysed in
buﬀer A (see above). The solution was then analysed after acidiﬁcation to
pH 4 followed by neutralization to pH 7 by adding HCl and NaOH,
respectively, to give a concentration of 3.8 mM in each sample.
Stopped-ﬂow ﬂuorescence spectra. The kinetics of the [1–93]ApoA-I
structural transition from pH 7 to pH 4 were monitored at 20 C on a Bio-
Logic SFM-300 stopped ﬂow ﬂuorimeter using an excitation wavelength
of 295 nm and monitoring the total ﬂuorescence emission change over
320 nm. One volume of 0.6 mg/ml peptide solution in buﬀer A (see above)
was mixed with ﬁve volumes of 5.4 mM glycine, 5.4 mM sodium acetate,
and 5.4 mM sodium phosphate at pH 7, and four volumes of 0.01 N HCl.
Binding to 8-anilino-1-naphthalenesulphonate (ANS). ANS binding
experiments were carried out on solutions containing [1–93]ApoA-I
(2.8 lM) and ANS (330 lM) in buﬀer A (see above). 8-Anilino-1-naph-
thalenesulphonate emission ﬂuorescence spectra were recorded in the
range 400–600 nm at an excitation wavelength of 395 nm and the slit
widths set at 5 nm [6]. Spectra were then recorded after acidiﬁcation to pH
4, and then after returning to pH 7.
Fibrils imaging. Samples for TEM were prepared by ﬂoating the
aggregate suspension on formvar/carbon-coated grids for 2–3 min, before
air-drying and staining them with 2% uranyl acetate. Samples were
examined in a Jeol JEM 1200 EX electron microscope operating at
180 kV. For AFM imaging, [1–93]ApoA-I solution (0.25 mg/ml) was
incubated at pH 4 and 25 C for two weeks and analysed as previously
described [7].Results
Expression and isolation of recombinant [1–93]ApoA-I as a
stable product
The 1–93 fragment of ApoA-I was expressed in bacterial
cells following an experimental strategy aimed at reducing
the intracellular degradation of the polypeptide during its
production. It was expressed as a chimeric protein obtained
by fusing the 93 residues polypeptide to glutathione
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lysates showed the presence of a major protein species in
IPTG-induced cells (Fig. 1A, lane 3) with a molecular mass
of about 36 kDa, as expected for the chimeric product, and
speciﬁcally recognised by an anti-ApoA-I antibody
(Fig. 1B, lane 3). In this sample, additional immunoposi-
tive species with a molecular mass lower than that of the
chimeric protein were also present (see below).
GST-containing proteins, selected on a GSH-agarose
aﬃnity column, were analysed by SDS–PAGE (Fig. 1A,
lane 4) and found to contain exclusively species recognized
by the anti-ApoA-I antibody (Fig. 1B, lane 4). Coomassie-
stained protein bands corresponding to these immunopos-
itive species were excised from the gel and digested in situ
with trypsin. The resulting peptide mixtures were directly
analysed by MALDI mass spectrometry. Mass signals were
mapped onto the anticipated ApoA-I sequence and showed
that the main product was the GST-[1–93]ApoA-I full
length chimeric protein (indicated in Fig. 1 by an arrow).
In addition to this product, small quantities of C-terminal
truncated [1–93]ApoA-I species were also identiﬁed.
The [1–93]ApoA-I moiety was released from the chime-
ric protein by targeted proteolysis, making use of a unique
cleavage site for thrombin positioned between the GST and
the [1–93]ApoA-I coding sequences. The proteolysis mix-
ture, analysed by SDS–PAGE and Western blot (Fig. 1A
and B, lane 5), was resolved by reverse-phase HPLC. The
major eluted fraction was found to contain a pure protein
species with the same electrophoretic mobility as the native
ﬁbrillogenic polypeptide [8] recognized by the anti-ApoA-I
antibody (Fig. 1A and B, lane 6). An aliquot of this protein
was analysed by electrospray mass spectrometry (ESMS)
showing a molecular mass of 10863.8 ± 0.1 Da, perfectly
matching the expected mass value of [1–93]ApoA-I with
the extra dipeptide Gly-Ser at the N-terminus originating
from the plasmid construct following thrombin cleavage
(10864.0 Da).Fig. 1. Analysis by SDS–PAGE of recombinant [1–93]ApoA-I. (A)
Coomassie staining; (B) Western blotting. Lane 1, native [1–93]ApoA-I
extracted from ex vivo ﬁbrils; lanes 2 and 3, soluble fractions prepared
from non-induced cells (lane 2) or induced cells (lane 3); lane 4, GST-
containing proteins selected by aﬃnity chromatography; lane 5, thrombin
proteolytic products; lane 6, HPLC puriﬁed [1–93]ApoA-I. The arrow
indicates the full length GST-fused [1–93]ApoA-I.CD spectroscopic analysis
The overall far UV CD spectrum of [1–93]ApoA-I at
neutral pH (Fig. 2A), with a minimum at 203 nm, indicates
that the peptide is highly unstructured under these condi-
tions. A marked change in the spectrum is observed at
pH 4, with the major minimum in the spectrum shifting
from 203 to 208 nm and a considerable increase in elliptic-
ity at 222 and 190 nm. Such spectral changes are consistent
with a transition to helical structure at pH 4, and are in
good agreement with the behaviour of the natural
[1–93]ApoA-I polypeptide [3]. In a similar way, we have
previously described the decay of the CD signal associated
with protein aggregation and precipitation as well as the
progressive loss of CD signal and the further aggregation
when the protein is left at pH 4 [3]. The pH-induced chang-
es in the spectrum can be reversed if NaOH is added within
a few seconds to neutralize the pH (Fig. 2A). Fig. 2B
reports the time dependence of CD spectra changes of
[1–93]ApoA-I upon exposure to acidic conditions. After
60 min of incubation at pH 4 the spectra show the disap-
pearance of the minimum at 222 and the persistence of a
second minimum at 205 nm that is suggestive of a transi-
tion to b-sheet structure.
Fluorescence spectroscopy
Tryptophan emission ﬂuorescence was monitored for
[1–93]ApoA-I at pH 7 and 4 (Fig. 2C). A blue shift from
347 to 342 nm occurs during the pH transition and is asso-
ciated with a decrease in the ﬂuorescence intensity in com-
plete agreement with the data obtained for the natural
peptide [3]. The eﬀect of the pH jump on the intrinsic ﬂuo-
rescence spectrum is consistent with the collapse of the pro-
tein core region and the exclusion of water molecules in the
vicinity of aromatic residues. This transition again is fully
reversible when the pH is rapidly returned to 7. The rate
of the conformational transition induced by low pH was
then investigated by monitoring the change in the trypto-
phan intrinsic ﬂuorescence under stopped ﬂow conditions
(inset of Fig. 2C). The 5% decrease of intrinsic ﬂuorescence
emission, expected on the basis of studies carried at the
equilibrium, is complete in approximately 2 s
(k = 1.01 s1) and 90% of this change takes place within
the lag time of the data acquisition (<2 ms).
ANS binding
The binding of the apolar dye ANS to [1–93]ApoA-I is
associated with an enhanced ﬂuorescence intensity and a
blue shift in the emission wavelength. Such changes are fre-
quently used to detect partially folded intermediate states
of globular proteins and are characteristic of solvent-
exposed hydrophobic clusters [9]. In the case of
[1–93]ApoA-I, binding of ANS to the protein at pH 7 leads
to a slight blue shift from 515 to 489 nm but no increase in
ﬂuorescence emission (compare Fig. 2D with inset).
Fig. 2. Spectroscopic analyses of [1–93]ApoA-I. (A) pH-induced transition of [1–93]ApoA-I secondary structure monitored by far UV CD. Spectra were
recorded at pH 7 (d), pH 4 (m), and then returned to pH 7 (s). (B) Time dependence of the induction of secondary structure of [1–93]ApoA-I at pH 4.
The far UV CD spectra were recorded at pH 7 and after a pH jump to pH 4 at the indicated time intervals. (C) Eﬀect of pH on the intrinsic ﬂuorescence of
[1–93]ApoA-I. Tryptophan emission was monitored at pH 7 (solid line), after a pH jump to 4 (dotted line), and then a return to pH 7 (dashed line). The
inset shows the rate of change of intrinsic ﬂuorescence acquired during the pH jump. The data were normalized by deﬁning the ﬂuorescence of the protein
at pH 7 as 100%. The continuous line through the data points represents the best ﬁt to a single exponential function. The symbol on the abscissa refers to
the ﬂuorescence intensity recorded at t = 0. (D) pH-induced binding of ANS to [1–93]ApoA-I. Symbols are as (A). ANS emission ﬂuorescence spectra were
recorded in the range of 400–600 nm at the excitation wavelength of 395 nm with the slit widths set at 5 nm. Spectra of the free dye at pH 7 and 4 are
shown in the inset.
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change of ANS ﬂuorescence reﬂecting the pH-induced
transformation into a partially folded conformation; at
pH 4 the ANS maximum emission shifts to 477 nm with
a considerable increase in ﬂuorescence intensity (Fig. 2D)
consistent with the behaviour previously ascribed to pro-
teins in a molten globule state [9].
The ANS–[1–93]ApoA-I complex at pH 4 dissociates
when the pH is returned to pH 7 and this reversibility is
consistent with data derived from the CD and intrinsic
ﬂuorescence spectra. The pH dependence of the ﬂuores-
cence intensity of the free dye is shown for comparison in
the inset of Fig. 2D.
Limited proteolysis
The conformational transitions of [1–93]ApoA-I were
investigated by limited proteolysis coupled with mass spec-
trometry both in the presence and in the absence of TFE
(20% at pH 7.5), which induces a stable helical state. The
patterns of preferential proteolytic sites were obtained
using a set of ﬁve proteases (trypsin, V8 protease, chymo-
trypsin, elastase, and subtilisin) as conformational probes[5]. For each protease, the appropriate enzyme/protein
ratio was carefully determined to generate a limited num-
ber of proteolytic events directed to the most ﬂexible and
solvent-exposed regions of the polypeptide chain. Proteo-
lytic fragments were separated by reverse-phase HPLC
and identiﬁed by ESMS, allowing the positions of the
cleavage sites to be assigned.
Fig. 3A summarizes the overall data from limited prote-
olysis experiments. In the absence of TFE, the polypeptide
chain is preferentially cleaved in its central region, between
residues 17 and 61, whereas the N-terminal region (residues
1–16) and the large segment 62–93 at the C-terminus are
protected. Similar results were obtained when the proteol-
ysis experiments were carried out in the presence of 20%
TFE.
Gel ﬁltration
The oligomeric state of the amyloidogenic [1–93]ApoA-I
fragment was assessed by gel-ﬁltration chromatography at
pH 7.5 both in the presence and in the absence of 20%
TFE. Interestingly, under native conditions the elution vol-
ume of [1–93]ApoA-I species was consistent with a dimeric
Fig. 3. (A) Schematic representation of the results obtained by limited
proteolysis experiments. Preferential proteolytic sites occurring in
[1–93]ApoA-I in the absence (native conditions) and presence of 20%
TFE are indicated by solid bars. (B) Investigation of the oligomeric state
of [1–93]ApoA-I by gel-ﬁltration chromatography, in the absence (thin
line) or presence (heavy line) of 20% TFE. The corresponding elution
volumes are indicated.
Fig. 4. Microscopic analyses of aggregated [1–93]ApoA-I. (A) Transmis-
son electron microscopy image of [1–93]ApoA-I ﬁbrils stained by 2%
uranyl acetate. (B) Tapping mode atomic force microscopy image of [1–
93]ApoA-I ﬁbrillar material showing a network of thin ﬁlaments coexis-
ting with globular aggregates. Scan size, 4.0 lm; Z range, 15 nm. Inset,
thin ﬁlaments and a ﬁbril approximately 1 lm long. Globular aggregates
are also present. Scan size, 1.8 lm; Z range, 10 nm.
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tein showed the behaviour of a monomeric species
(Fig. 3B).
Fibril formation
The formation of amyloid ﬁbrils at pH 4 was monitored
by electron microscopy and atomic force microscopy.
Fig. 4A shows an electron microscopy image of a ﬁbrils nest
obtained with recombinant [1–93]ApoA-I. Images obtained
by AFM are presented in Fig. 4B. Narrow protoﬁlaments
and well-deﬁned ﬁbrils were detectable after 72–90 h of
incubation at pH 4, consistent with the rate observed for
the native protein [3]. Fibrillar structures coexist with glob-
ular aggregates whose height is between 4 and 10 nm. The
heights of protoﬁlaments and mature ﬁbrils are
0.8 ± 0.3 nm and 2.4 ± 0.6, values in agreement with those
measured by tapping mode AFM in air for ex vivo amyloid
ﬁbrils formed by Leu174Ser ApoA-I [7]. The relatively
small height values measured by AFM in air are associated
with sample drying, which results in dehydration and possi-
bly deformation of the ﬁbrils upon adhesion to the mica
substrate. On the other hand, for Leu174Ser ApoA-I ﬁbrils,
a diameter of about 7 nm was estimated by electron micros-
copy [10] and a height value of 11 nm was measured by
AFM under fully hydrated conditions [7].
Discussion
In the present study an eﬃcient strategy to produce a
recombinant version of the 1–93 amyloidogenic domainof ApoA-I has been established. The investigation of the
conformation of this polypeptide in solution indicates that
in physiological conditions the protein has a highly unfold-
ed structure. A decrease in the pH value from 7 to 4 induces
a predominant a-helical structure, by inducing the conver-
sion of the protein from a random coil to a helical/molten
globule state, capable to bind ANS. This transition, com-
plete within 2 s and fully reversible when the pH is returned
to 7, is followed by the appearance of a signiﬁcant b-sheet
component. The helical/molten globule intermediate dis-
plays a strong propensity to oligomerize; indeed attempts
to analyse this intermediate by gel-ﬁltration failed due to
the rapid formation of insoluble species (data not shown).
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helical state was further investigated by stimulating the
helical conformation at neutral pH by treatment with
20% triﬂuoroethanol [11]. Limited proteolysis experiments,
performed both in the absence and in the presence of the
co-solvent, indicated a nearly identical distribution of pref-
erential proteolytic sites, with the C-terminal region of the
polypeptide chain being inaccessible to proteases in both
conditions. Gel-ﬁltration suggests that [1–93]ApoA-I, while
dimeric in native conditions, is monomeric in the presence
of TFE. The inaccessibility of the C-terminus in native con-
ditions might then be a consequence of the dimeric struc-
ture of the polypeptide, whereas the local stabilization
induced by TFE makes this region resistant to proteolytic
attack in the monomeric form.
Analyses by electron and atomic force microscopy have
demonstrated that [1–93]ApoA-I generates typical amyloid
ﬁbrils following incubation at pH 4 for lengths of time
comparable to those required by the natural counterpart.
Our results on recombinant [1–93]ApoA-I conﬁrm and
expand the data obtained with its natural counterpart and
focus our attention on the kinetics and stability of the heli-
cal/molten globule state, as a key intermediate in the multi-
step ﬁbrillogenic process. These ﬁndings also encourage the
production of the variants of this polypeptide described in
patients aﬀected by ApoA-I associated amiloidoses. A
detailed comparative study on the conformational dynam-
ics and ﬁbrillogenic potential of mutated forms versus wild
type [1–93]ApoA-I would contribute greatly to the compre-
hension of the molecular mechanism by which mutations in
ApoA-I promote amyloid deposition.
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